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Abstract 
An array of over the counter ophthalmic solutions (eye drops) is available for the 
self treatment of minor ophthalmic disorders. They are used allover the world for the 
treatment of minor eye episodes including redness, dry eye and tear generation. Because 
components in ophthalmic solutions may cause adverse reactions, there is a need for 
modern, rugged chemical analysis techniques for these components using 
straightforward, inexpensive and readily available instrumentation and methods. This 
work focuses on the chemical analysis of ophthalmic solutions in three major areas; 
preservatives, lubricants, and active components. Each feature plays an integral part in 
the total effectiveness of the ophthalmic solution, so several components were studied 
extehsively with different chromatographic techniques. The emergence of new complex 
matrices which target multi symptom relief in the eye makes development of 
straightforward new techniques increasingly challenging. 
One of the three primary aspects of this work was the analysis of preservatives, 
which is important for inhibiting microbial growth and ensuring safety. Benzalkonium 
chloride (BAC) is widely used in ophthalmic solutions and is often difficult to analyze 
due to its multicomponent nature. Further, the several homologues do not posses identical 
bactericidal activity, with the Cl2 homologue most effective against yeast and fungi, the 
C14 homologue against gram-positive bacteria, and the C16 homologue against gram­
negative bacteria. A fast, simple, isocratic, high performance liquid chromatography 
based in ultra violet (HPLC-UV) detection method was sufficient to fully separate the 
BAC homologues from each other and from other components in typical solutions. 
Second, lubricants, or demulcents, are often present in ophthalmic solutions and 
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are used to control the solution viscosity. Additionally, they offer a medicinal benefit, 
relieving pain in inflamed or irritated mucous membranes. Three different demulcents 
were studied: polyvinylpyrrolidone (PVP), polyethylene glycol 400 (PEG400) and 
glycerin. As PVP and PEG400 are polymeric, size exclusion chromatography (SEC) is 
the technique of choice, however, most SEC methods focus on molecular weight 
characterization rather than quantitative analysis. In this work, total PVP in ophthalmic 
solutions was determined using the unusual combination of size exclusion 
chromatography, ultraviolet-visible detection and quantitation of an analyte peak that 
elutes before the void volume disturbance. A more conventional size exclusion 
chromatography method was used for the simultaneous determination of PEG400 and 
glycerin in ophthalmic solutions, using size exclusion chromatography, with refractive 
index detection. 
Third, analysis of the active component, along with possible degradants and 
impurities is critical in any ophthalmic solution. The increasing attention that degradants 
and impurities are receiving from the regulatory authorities makes these methods 
important to the development of ophthalmic solutions. One challenge in ophthalmic 
solutions is the analysis of oxymetazoline hydrochloride (OXY) and its known 
degradation product (N-(2-arninoethyl)-2-[4-(1,ldimethylethyl)-3-hydroxy-2,6­
dimethylphenyl]-acetarnide) (OXY-DEG). Although a number of HPLC methods have 
been developed to determine OXY in a variety of products, none of these methods also 
determined OXY -DEG, which appears at much lower concentration. In this work, a 
straightforward, isocratic reversed-phase HPLC-UV method was sufficient to quantify 
both OXY and OXY -DEG in a single analysis, although their concentrations are orders of 
iv 
magnitude different. Forced degradation studies performed during method validation 
revealed that OXY -DEG is likely a base hydrolysis product of OXY. 
In the analysis of over the counter medications such as ophthalmic solutions, 
which are widely used at low cost, there is an increasing need for new analytical methods 
that are low cost, simple to operate and use straightforward instrumentation, while 
maintaining similar sensitivity and reproducibility requirements to techniques employing 
more sophisticated instrumentation. In this work, several straightforward techniques for 
the analysis of components in ophthalmic solutions, each of which represents an 
improvement over previous literature techniques, are demonstrated. 
v 
magnitude different. Forced degradation studies performed during method validation 
revealed that OXY -DEG is likely a base hydrolysis product of OXY. 
In the analysis of over the counter medications such as ophthalmic solutions, 
which are widely used at low cost, there is an increasing need for new analytical methods 
that are low cost, simple to operate and use straightforward instrumentation, while 
maintaining similar sensitivity and reproducibility requirements to techniques employing 
more sophisticated instrumentation. In this work, several straightforward techniques for 
the analysis of components in ophthalmic solutions, each of which represents an 
improvement over previous literature techniques, are demonstrated. 
v 
Acknowledgements 
I would like to thank my research advisor Dr. Nicholas Snow for the opportunity 
to be part of his group and the unlimited support that he has provided during the years 
that I spent at Seton Hall University. I cannot. thank him enough for his valuable lessons 
in separation science and his encouragement to complete my research. I will always be 
grateful to him for his advice, vision, excellence and for what I learn in the field of 
chromatography as a member of his group. His work ethics and professionalism will 
always serve as a model for me in my own career. 
I am thankful to Dr. Yuri Kazakevich for being part of my matriculation and my 
dissertation committees. Additionally, I am thankful to Dr. Kazakevich for providing 
valuable feedback in my research proposal and always being available to discuss 
chromatography. 
I would like to thank Dr. W. R. Murphy for being part of my research proposal 
review and dissertation committees. His valuable comments made my research proposal 
and this work more acceptable. 
I am grateful to Dr. John Sowa for his willingness to meet with me mUltiple times 
and discuss degradation pathway of active components in ophthalmic solutions. His 
advice to investigate specific stress studies enabled me to confirm degradation pathway 
of several actives components in ophthalmic solutions. 
Thanks to the research groups of both Dr. Snow and Dr. Kazakevich for their 
comments during my rehearsal of the matriculation and Ph.D. seminars. 
vi 
I would like to thank the Chemistry and Biochemistry Department of Seton Hall 
University for their support during my years at Seton Hall University. 
The Johnson & Johnson group of consumer companies is acknowledged for the 
resources and economic support that they provided over the years in order for me to 
complete my research. I would like to recognize the support of the following colleagues 
at J&J Mr. Gary McNeill, Dr. Kevin Bradley, Dr. Ken Karaisz, Dr. Jonine Greyling, Dr. 
Ming Bai, Mr. Ani Desai, Mr. John Urban, Mrs. Varsha Sheth, Mrs. Dianna Diaz, and Mr. 
Ken Holeva. 
Last but not least I would like to thank my family for their support and 
encouragement to complete my degree. I thank my son Antonios for being so 
understanding when he was accompanying me at school and waiting quietly for me to do 
my research work. I thank my daughter Christina for spending time away from her father 
and always question me the nights that I return late from school "you were at school 
again?",. I thank my wife Maria for being so patient over the years with my attempts to 
complete the program. She always had words of encouragement and support. I thank my 
mother Despina, who taught me to understand what is important in life. Certainly 
education was high in her list. Maria, Antonios, Christina, and Mom, many thanks, I 
couldn't have done it without your support!! 
vii 
Dedication 

This work is dedicated to my Family 

& 
In loving memory of my father, Antonios Tavlarakis, who left early from this world but 
his valuable lessons in life had a profound impact on my life as well 
viii 
TABLE OF CONTENTS 

Title Page ..............................................................................................................................i 

Signature Page .................................................................................................................... ii 

Abstract. ............................................................................................................................. iii 

Acknowledgement ..............................................................................................................vi 

Dedication ........................................................................................................................ viii 

Table of Contents .................... .'........................................................................................... ix 

List of Figures ................................................................................................................... xii 

List of Tables .................................................................................................................... xi v 

Chapter 1: Introduction ............................................................................................. 1 

1.1 Historical Overview ....................................................................................................... 1 

1.2 Formulation Overview ...................................................................................................5 

Chapter 2: Preservatives.......................................................................................... 10 

2.1 Introduction.................................................................................................................. 10 

2.2 Experimental ................................................................................................................ 13 

2.2.1 Reagents and Chemicals .................................................................................... 13 

2.2.2 Equipment ......................................................................................................... 14 

2.2.3 Chromatographic Conditions ............................................................................ 14 

2.2.4 Testing Parameters ............................................................................................ 14 

2.2.4.1 Specificity............................................................................................ 15 

2.2.4.2 Accuracy.............................................................................................. 15 

2.2.4.3 Linearity .............................................................................................. 15 

2.2.4.4 System Performance ............................................................................ 16 

2.2.4.5 Precision .............................................................................................. 16 

2.2.4.5.1 System Precision ................................................................... 16 

2.2.4.5.2 Repeatability .......................................................................... 16 

2.2.4.5.3 Intermediate Precision ........................................................... 16 

2.2.4.6 Robustness ........................................................................................... 17 

2.2.4.6.1 Chromatographic parameters ................................................ 17 

2.2.4.6.2 Solution Stability ................................................................... 17 

2.3 Results and Discussion ................................................................................................ 17 

2.3.1 Developmental Work......................................................................................... 17 

ix 
2.3.2 Experimental Work ...........................................................................................20 

2.4 Conclusion .: ................................................................................................................. 32 

Chapter 3: Demulcents (Polyvinylpyrrolidone)..................................................... 33 

3.1 Introduction.................................................................................................................. 33 

3.2 Experimental ................................................................................................................37 

3.2.1 Reagents and Chemicals .................................................................................... 37 

3.2.2 Instrumental Conditions .................................................................................... 37 

3.2.3 Testing Parameters ............................................................................................ 38 

3.3 Results and Discussion ................................................................................................40 

3.3.1 Developmental Work ..................................................................................... : ...40 

3.3.2 Experimental Work ...........................................................................................45 

3.4 Conclusion ................................................................................................................... 58 

Chapter 4: Demulcents (PEG400 and Glycerin) ..................................................59 

4.1 Introduction..................................................................................................................59 

4.2 Experimental ................................................................................................................ 67 

4.2.1 Reagents and Chemicals .................................................................................... 67 

4.2.2 Instrumental Conditions ....................................................................................68 

4.2.3 Testing Parameters ............................................................................................ 69 

4.3 Results and Discussion ................................................................................................71 

4.3.1 Developmental Work .........................................................................................71 

4.3.2 Experimental Work ...........................................................................................76 

4.4 Conclusion ...................................................................................................................93 

Chapter 5: Ophthalmic Active Components ..........................................................96 

5.1 Introduction...................................................................................................................96 

5.2 Experimental .............................................................................................................. 104 

5.2.1 Reagents and Chemicals .................................................................................. 1 04 

5.2.2 Equipment ............................ : .......................................................................... 104 

5.2.3 Sample and Standard Preparation .................................................................... 105 

5.2.4 Instrumental Conditions .................................................................................. 105 

5.2.5 Calculations ..................................................................................................... 106 

5.2.6 Testing Parameters ........................................................................ , ................. 107 

5.2.6.1 Specificity ............................................................................................. 107 

x 
5.2.6.2 Accuracy....... ~ ....................................................................................... 108 

5.2.6.3 Linearity ............................................................................................... 108 

5.2.6.4 Relative Response Factor ..................................................................... 109 

5.2.6.5 Limit of Detection ................................................................................ 109 

5.2.6.6 Limit of Quantitation ............................................................................ 11 0 

5.2.6.7 System Performance ............................................................................. 110 

5.2.6.8 Precision ............................................................................................... 110 

5.2.6.8.1 System Precision .................................................................... 110 

5;2.6.8.2 Repeatability........................................................................... 111 

5.2.6.8.3 Intermediate Precision ............................................................ 111 

5.2.6.9 Robustness ............................................................................................ 111 

5.2.6.9.1 Method Parameters ................................................................. 111 

5.2.6.9.2 Solution Stability .................................................................... 112 

5.3 Results and Discussion .............................................................................................. 112 

5.3.1 Developmental Work ....................................................................................... 114 

5.3.2 Experimental Work ......................................................................................... 118 

5.4 Conclusion ................................................................................................................. 137 

Overall Conclusion .......................................................................................................... 138 

References...................................................................................... : ................................. 141 

xi 
List of Figures 

Figure I: Structure of benzalkonium chloride ................................................................... 12 

Figure 2: Overlay chromatograms several different ophthalmic formulations ................. 19 

Figure 3: System performance chromatogram ..................................................................21 

Figure 4: Expanded overlay chromatogram of stress studies ............................................23 

Figure 5: Linearity graph of BAC ..................................................................................... 24 

Figure 6: Robustness overlay chromatogram of critical method parameters ....................30 

Figure 7: Structure of polyvinylpyrrolidone ...................................................................... 35 

Figure 8: UV spectrum of polyvinylpyrrolidone .............................................................. .41 

Figure 9: Chromatogram of polyvinylpyrrolidone ............................................................43 

Figure 10: Overlay chromatogram of ophthalmic formulation, standard of povidone, and 

formulation without polyvin~lpyrrolidone ....................................................................... .46 

Figure 11: Overlay chromatogram of different molecular weight polyvinylpyrrolidone 

polymers, and polyvinylpyrrolidone with its monomer ................................................... .47 

Figure 12: Expanded overlay chromatogram of stress studies ......................................... .49 

Figure 13: Linearity graph of povidone .............................................................................50 

Figure 14: Structures of glycerin and PEG400 .................................................................. 61 

Figure 15: Transesterification reaction oftriglycerides to fatty acid methyl ester ............ 63 

Figure 16: Sample chromatogram with hydroxypropyl methylcellulose (HPMC), 

PEG400, and glycerin ........................................................................................................73 

Figure 17: Chromatogram of PEG400 and glycerin ..........................................................75 

Figure 18: Different sample chromatograms contain PEG400 and glycerin .....................77 

Figure 19: Overlay chromatograms of PEG400 and glycerin working standard with 

ophthalmic solutions that doesn't contain PEG400 and glycerin .......................................78 

Figure 20: Overlay chromatograms of stress studies .........................................................80 

Figure 21: Linearity graph of PEG400 .............................................................................. 81 

Figure 22: Linearity graph of glycerin............................................................................... 83 

Figure 23: Imidazoline structures of tetrahydrozoline and naphazoline ............................99 

Figure 24: Oxymetazoline structure ................................................................................ 101 

Figure 25: Structure of oxymetazoline degradation product (N-(2-aminoethyl)-2-[4-(1, 1­
dimethylethyl)-3-hydroxy-2,6-dimethylphenyl ]-acetarnide) ........................................... 103 

Figure 26: Overlay chromatogram of ophthalmic solution sample and degradation 

standard mixture .............................................................................................................. 113 

Figure 27: UV spectra of oxymetazoline and OXY -DEG ............................................... 115 

Figure 28: Chromatograms ofoxymetazoline assay and degradation method ................ l17 

xii 

------------------
Figure 29: Typical chromatogram for oxymetazoline Hel standard of 100 llL injection 

volume ............................................................................................................................. 119 

Figure 30: Overlay chromatogram of stress studies for oxymetazoline standard ........... 120 

Figure 31: Formation of hydrolyzed product of oxymetazoline ...................................... 122 

Figure 32: Linearity graph of oxymetazoline assay method ........................................... 124 

Figure 33: Linearity graph of oxymetazoline degradation method ................................. 127 

Figure 34: Linearity graph of oxymetazoline assay method at 280 nm and 100 llL 

injection volume .............................................................................................................. 129 

xiii 
LIST OF TABLES 

Table I: Linearity parameters of BAC ..............................................................................25 

Table 2a: System precision results .................................................................................... 27 

Table 2b: Intermediate method precision results ...............................................................27 

Table 2c: Accuracy results .................................................... · ............................................. 27 

Table 3: Robustness results ............................................................................................... 28 

Table 4: Solution Stability results for BAC ....................................................................... 3I 

Table 5: Linearity parameters of polyvinylpyrrolidone............................................. ~ ....... 51 

Table 6a: System precision results .................................................................................... 52 

Table 6b: Intermediate method precision results ...............................................................52 

Table 7a: Accuracy results .................................................................................................54 

Table 7b: Robustness results .............................................................................................54 

Table 8a: Assay results of ophthalmic solutions using different raw material.. ................ 56 

Table 8b: Water content .....................................................................................................56 

Table 8c: Assay results of ophthalmic solutions taking into account water content. ........ 56 

Table 9: Solution stability results ......................................................................................57 

Table 10: Linearity parameters of PEG400 .......................................................................82 

Table 11: Linearity parameters of glycerin ................................ ; ...................................... 84 

Table 12a: System precision for PEG400 and glycerin .....................................................86 

Table 12b: Intermediate method precision results for PEG400 .........................................86 

Table 12c: Intermediate method precision results for glycerin .........................................86 

Table 13a: Accuracy results for PEG400 ..........................................................................87 

Table 13b: Accuracy results for glycerin ...........................................................................87 

Table I4a: Robustness studies for PEG400 .......................................................................89 

Table 14b: Robustness studies for glycerin ....................................................................... 89 

Table 15a: Assay results of ophthalmic solutions using different sources of glycerin......90 

Table I5b: Water content of glycerin standards ................................................................90 

Table 15c: Assay results of ophthalmic solutions corrected for water content .................90 

Table 16a: Assay results of ophthalmic solutions using different sources of PEG400 .....92 

Table 16b: Water content of PEG400 standards ................................................................ 92 

Table 16c: Assay results of ophthalmic solutions corrected for water content. ................92 

Table 17: Standard solution stability of PEG400 and glycerin .........................................94 

xiv 
Table 18: Sample solution stability ................................................................................... 95 

Table 19: Linearity parameters of Oxymetazoline .......................................................... 123 

Table 20: Linearity parameters of Oxymetazoline degradation ...................................... 126 

Table 21: Unearity parameters of Oxymetazoline degradation at 100 ilL injection ....... 128 

Table 22a: System precision comparison table of 10 and 100 ilL injection ................... 131 

Table 22b: Method precision comparison table of 10 and 100 ilL injection ................... 131 

Table 22c: Comparison table of OXY -DEG by two different experiments .................... 131 

Table 23: Accuracy results for OXY Assay .................................................................... 133 

Table 24: Comparison table of OXY Assay of 10 and 100 ilL injection ....................... 134 

Table 25: Solution stability results .................................................................................. 136 

xv 

Chapter 1: Introduction 
1.1 Historical Overview 
The history of ophthalmic solutions coincides with the history of Ophthalmology, 
the branch of medicine that deals with the anatomy, physiology and diseases of the eye. 
The word has Greek roots from the word "ophthalmos" which means eye and the word 
"logos" which means speech, word, and communication of thought with words. Literally 
the word ophthalmology means the science of eyes [1]. 
Due to unrecorded uncertainties in the history of ophthalmology, it is impossible 
to say where exactly the treatment of the eyes began, but the earliest mention of any 
medical matter is found to go back as far as 2000 B.C. Any medical treatment at that time 
was totally at the hands of priests. The first written document about treatment of the eye 
came later, around 1650 B.c. in Egypt where a 110 page document (Papyrus Ebers) was 
found that described all the diseases and remedies that were known to Egyptians of that 
time. From the 110 pages, around 8 pages were dedicated to diseases of the eye and 
treatment for such diseases. Some of the remedies at the time used onions, castor oil, 
pomegranate, copper salts, hemlock and opium. Learning and performing medicine at 
that time was done at temples, as priests were doctors as well. 
The separation of scientific medicine from temple practice was not completed 
until 460 B.C. during the golden age of Greece. Hippocrates considered the father of 
medicine is credited with accomplishing this separation by introducing the science of 
observation and reasoning into medicine. 
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In those days, ophthalmic diseases were treated with venesection, cupping and 
occasionally by drawing the humours away from the eye. Chronic diseases were treated 
mainly with local application of milk of women, gall of goats, and various preparations of 
copper, iron, and lead. For the next 800 years and from the time of Hippocrates to the end 
of the era of Roman Empire, Greek medicine dominates the field and was practiced not 
only in Greece but extended to Rome and Alexandria. 
The Alexandrian school introduced Collyria for treatment of eye diseases. It was a 
solid substance made up of several secret ingredients in a cake form with gum being the 
basis of the formulation. Prior to its application a fragment of the cake was dissolved in 
water, oil, milk of women, urine, bile, or saliva. 
During this time the disease that was scourge to the eyes was trachoma, an 
infectious disease caused by bacteria which produce roughening of the inner surface of 
the eyelids, causing the eyelids to turn inward and scratch the cornea eventually creating 
a painful form of blindness. 
The work of three men dominated medicine during this period: Celsus, Pliny, and 
Galen. Celsus wrote "De Medica or De Medicina" in A.D. 29, a compilation of detailed 
description of couching for cataract [2]. A humouraI implication, collected in a space 
between the pupil and the lens, obstructing visual spirits. When this was fully developed 
it could be displaced away from the front of the eye by means of an operation. Pliny 
made the observation that the eyes of nocturnal animals were brilliant in the dark, in 
agreement with other Roman writers of this period that were interested in the problem of 
why the pupil is black. Pliny also credits the discovery of glass making to the 
Phoenicians. In these early days, glass was used as an art; later glass is used to correct 
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vision. Galen (A.D. 131-201) studied the anatomy of the eye and like Hippocrates, 
thought that the crystalline body (lens) was the most important part of the organ of vision. 
He believed that the retina was to perceive the alterations which occur in the crystalline 
body of the eye and to communicate them to the brain. He shared the same ideas for 
cataracts as Celsus. 
During the period of A.D. 630-1375, medieval scientists combined theory and 
. practice. They found it natural to study the eye with the practical applications of that 
knowledge. This period also marked the rise of Islam and conquest of the Eastern part of 
the Mediterranean. One unfortunate event it was the burning of the famous library of 
Alexandria, resulting in a big gap in the ancient writings that was never restored. The 
eastern knowledge of medicine began to filter into the west during the Crusades and 
within a decade the torch had been handed on to Western Europe. 
16thDuring the and 17th centuries, the facts of physiological optics began to 
slowly be accepted. Robert Hooke first measured the minimum visual angle which the 
basis of our present day test types. However, clinical progress was not made until the 
beginning of the 19th century especially in the area of cataracts. First, Daviel of France 
published the operation of extracting the opaque lens from the eye through the interior 
chamber and later Brisseau convinced the Academie Royal des Sciences that a cataract is 
really an opaque lens. 
19thThe century was marked by many discoveries in ophthalmology, 
bacteriology, by the introduction of anesthesia, and antiseptic surgery just to mention a 
few. However, from the perspective of ophthalmic solutions, bacteriology and the 
introduction of antiseptic surgery highlight the importance of a bacteria free environment 
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and the tools used for eye surgery. In those days, ophthalmic solutions were kept in 
corked glass bottles, unpreserved, and were administered with a pipette. Current studies 
show that solutions stored under these conditions are 94% contaminated [3]. These 
results are not surprising since the pipette, the open bottle or the cork can come in contact 
with a pathogenic microorganism, even in a clean environment. As Pasteur famously 
demonstrated in 1864, contamination from microorganisms can be prevented with savvy 
packaging [4]. 
Ophthalmic solutions in twentieth, and twenty-first centuries are marked in 
improvements in packaging, preservation, and delivery systems that improve product 
lifetime and sustain release of the drug in the eye. Packaging moved from glass cork 
bottles to a sterile glass bottles with a screwed dropper, and in some instances to a plastic 
bottle with a tip for directly delivering the drop into the eye. 
Preservation of ophthalmic solutions is very important and is required by the Food 
and Drug Administration for topical ophthalmic multidose bottles. More specifically, the 
United States Pharmacopeia specifically states that ophthalmic solutions in multidose 
containers should contain suitable substances to prevent or destroy micro-organisms 
when accidentally introduced when the container is opened during use. Despite concerns 
in recent years about the presence of benzalkonium chloride and the development of 
other preservative systems, benzalkonium chloride is by far the preservative system of 
choice in ophthalmic solutions. 
Recent advances in ophthalmic solutions have focused on sustained release 
formulations for delivering the drug into the eye and formulations that target multiple 
symptoms at the same time. Because of the unique characteristics of the eye and the 
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multiple barriers that the formulation has to go through, the development of ophthalmic 
formulations is extremely challenging. In the next section, "formulation overview" these 
challenges are described in more detail. 
1.2 Formulation Overview 
Ophthalmic solutions are among of the most challenging and fascinating tasks 
facing product development researchers because the eye is well protected against the 
absorption of foreign materials, including therapeutic formulations. The easy accessibility 
of the eye makes this organ suitable for topical administration of a medication. However, 
any drug delivered through that route must go through several barriers in the precorneal 
area before the anatomical barriers of the cornea. Because of these barriers, only a small 
dose of the drug will reach the eye. 
Upon topical administration of an ophthalmic solution in the eye, tear flow 
immediately increases and washes it away in a short period of time. Under normal 
conditions, the eye can accommodate a small volume before overflowing. Commercial 
eye drops typically deliver about 30 ~L to 50 ~L per drop and most of this amount will 
drain out of the eye with the first blink. Due to that loss, only a small amount (about 10 
~L) will remain in the eye to penetrate the COTllea and the inner tissue of the eye [5]. 
Consequently there is a very small time window, approximately 5 minutes, for any drug 
introduced topically to be absorbed by the eye and in many cases no more than 2% of the 
drug absorbed [5-7]. By contrast, a considerable amount of drug is absorbed by the 
nasolacrimal duct, with its greater surface area and higher permeability of the mucosal 
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membrane compared to that of the cornea [8]. 
I 
Corneal permeability of the drug is low for ophthalmic solutions administered 
topically. The human cornea has 5 tissues with 3 of them, the epithelium, the 
endothelium, . and the inner stroma being the main barriers to absorption. The epithelium 
is relatively lipophilic and has low porosity and high tortuosity, which makes it the main 
barrier for hydrophilic drugs. The middle stromal layer, which consists mainly of water 
interspersed with collagen fibrils and accounts for most of cornea's thickness, is the main 
barrier for lipophilic drugs [5,9-11]. All these barriers result not only in low penetration 
of the drug but in systemic side effects of the ophthalmic drugs with topical 
administration [12-13]. 
An ideal ophthalmic solution will provide deep penetration beyond the initial 
I layers of the eye. Consequently this can only be achieved by sustained drug release and 
I the ability to remain in the vicinity a front of the eye for a long period of time. 
~ The raw materials used in ophthalmic solutions must be of the highest quality ~ 
available and each lot of the ingredients must be qualified against multiple 
pharmacopoeia specifications prior to its use, in order to be safe and to meet global 
requirements. Also, each ingredient has a specific function in the formulation. Some 
general characteristics of ingredients that must be studied are concentration, tonicity, 
viscosity and pH adjustment (buffer solutions), active ingredient stabilizers, and 
component solubility. Selection of all the formulation components is done based on the 
physical and chemical compatibility between them and biocompatibility with delicate 
ocular tissue. 
The pH and buffering of ophthalmic solutions is very important to product 
6 
stability and product quality in general. Ideally an ophthalmic solution would be buffered 
at pH 7.4, which is the pH of tear fluid. In addition to formulation stability, pH 
adjustment enhances comfort, safety, and activity of the product. The pH of ophthalmic 
solutions is usually buffered within a range to provide maximum product stability and 
shelf life of about two years. The pH value expected to be maintained within the range 
during the entire shelf life of the product. An optimal pH range for ophthalmic 
formulations is between 7.0-7.4 and usually phosphate buffer is selected as a starting 
point. 
Well buffered solutions prevent unwanted changes in pH due to hydroxyl ion 
release from the glass bottles in which solutions are stored. Unwanted pH changes can 
create discomfort to the patient especially for changes outside the tolerable pH range 
(6.6-8.5) of the cornea. Larger pH changes, outside the pH range of 4 to 10 will create 
permeability changes. 
Precipitation and deterioration of the drug can occur after administration for 
formulations with pH that is not close to physiological pH of tears. The introduction of 
any formulation into the eye that causes discomfort due to precipitation is likely to 
stimulate tear production and increase the rate of drug removal from the eye making such 
formulations unsuitable for their intended use. 
Sterility is of high importance and every ophthalmic solution must be 
manufactured under conditions to render it sterile in its final package and for the shelf life 
of its product. Each lot of product should be tested and released with appropriate 
pharmacopoeia methods to verify product sterility. There are different methods (steam, 
dry-heat, gas, ionizing radiation, filtration and aseptic processing) of sterilization of 
7 



ophthalmic solutions and selection of the method is done based on the compatibility of 
active components with other ingredients in the formulation. To reduce the biggest 
source of microbial contamination, only sterile purified water should be used preparing 
ophthalmic solutions. 
Clarity is one of the ophthalmic solution properties, as by definition solutions are 
expected to be free of foreign mater and undissolved material. It is a critical parameter, so 
samples are tested to verify that they are free of foreign matter. Clarity is enhanced by 
filtration and it is essential that this is performed by equipment that is clean and does not 
contribute to contamination of the formulation. The overall process can be done in a! 
I combined step with sterilization and must take place in a clean environment. Solutions that fail the clarity test should not be used for instillation to the eye due to productj j instability and possible discomfort to the eye which will stimulate tear production and j 
. drug removal. j 
i Tonicity is a measure of the osmotic pressure of two solutions separated by 
I semipermeable membrane [14]. It is important to the eye that ophthalmic solutions 
I should be adjusted for correct tonicity. When the concentration of the solute is higher 
outside the membrane (cell membrane) the solution is hypertonic, when the concentration 
of the solute is lower outside the membrane the solution is hypotonic and when the 
concentration is the same in both sides of the membrane the solution is isotonic [15] 
Depending on the drug and its intended use, solutions can be prepared with 
different tonicity. The external part of the eye is more tolerant to tonicity variations. An 
isotonic solution is more important for intraocular use. However, in some cases of dry 
eye, tear fluid is reported to be hypertonic and a hypotonic artificial product is used to 
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balance this condition. Common ingredients used for the tonicity adjustment of the 
ophthalmic solutions are sodium chloride, potassium chloride, manitol, dextrose, 
propylene glycol, and glycerine. 
There are three additional areas very important to ophthalmic formulations: 
preservation, demulcents, and active components. These are discussed extensively in the 
next chapters. In these chapters the importance of preservatives in ophthalmic solutions 
was discussed and one of the most widely used preservative systems (benzalkonium 
chloride) in over the counter ophthalmic solutions was studied. Two chapters will focus 
on the study of demulcents or lubricants in ophthalmic solutions. Demulcents in over the 
counter ophthalmic solutions have a dual role, to control viscosity and offer pain relief in 
irritated mucous membranes. Polyvinylpyrrolidone. PEG400 and glycerin are the three 
demulcents which were studied in the following chapters. Vasoconstrictors are one of 
the major areas of active components in ophthalmic solutions. They are used primarily 
for the treatment of redness and minor irritations in the eye. One of the vasoconstrictors 
used in ophthalmic solutions is oxymetazoline and it is member of other vasoconstrictors 
that have similar chemical structure and exhibit the same degradation profile. 
Oxymetazoline and its known degradant were studied in the next chapters. 
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Chapter 2: Preservatives 
2.1 Introduction 
Preservatives are chemical substances that are used in ophthalmic solutions to 
preserve the integrity of the solution by killing microbes or inhibiting microbial growth, 
thus extending the product shelf life. This is extremely important given the environment 
in which these solutions are kept and in that how they are often mishandled. Solutions 
kept in medicine cabinets, purses, and pockets, exposed in extreme conditions of heat, 
humidity, provide a good environment for microbial growth. Often, users mishandle 
multidose bottles by touching the tip of the dropper with their fingers or with their eyes, 
introducing contamination. There are several types of preservatives within two major 
classifications, but only a few are applicable in ophthalmic solutions. Preservatives are 
classified in two major categories, antioxidants and antimicrobial. Antioxidants are 
inhibit oxidation reactions that disrupt the cell metabolism. Antimicrobial preservatives 
kill or inhibit the growth of microbes introduced during manufacturing or usage. The 
most commonly used preservative in ophthalmic solutions is benzalkonium chloride, 
which kills microorganisms by disrupting cell membranes. 
Surfactants are also a major area of preservatives within the antimicrobial 
category. They are classified as cationic, anionic, nonanionic and amphoteric based on 
their net charge in solution and chemical structure. When dissolved in water surfactants 
reduce the surface tension between the liquid/vapor surface or at the water/oil interface. 
Cationic surfactants ionize in aqueous solution to produce positively charged organic ions 
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that are responsible for surface activity. Cationic surfactants are widely used in 
ophthalmic formulations' because of their low toxicity, high surface activity, aqueous 
solubility, and their high preservative efficacy that often reduces or eliminate the need for 
additional preservatives. Benzalkonium chloride preservative efficacy is well established 
and it is widely used in ophthalmic solutions. Its physical attributes of high water 
solubility, and lack of color or odor in solution makes the BAC quaternary ammonium 
salt suitable as a preservative in ophthalmic solutions. 
Benzalkonium chloride (BAC) is a mixture of alkylbenzyl dimethylammonium 
chlorides of various alkyl chain lengths with a general formula: [C6HsCH2N(CH3hR]Cl, 
in which R represents a mixture of alkyls with n-C12H25, n-C J4H29, and n-CJ6H33 
comprising the major portion of the BAC. The chemical structure of benzalkonium 
chloride is presented in Figure 1. It is commonly used as an antiseptic with the greatest 
activity associated with the CJ2-C14 alkyl derivatives. 
Benzalkonium chloride has been in clinical use since 1935 and is an active 
ingredient in a wide variety of prescription and over-the-counter products. Is generally 
found in topical solutions for cleaning, minor wound care and disinfecting in 1 :750 
dilution with water, or about 0.133%. For major wound care, mucous membrane and 
ophthalmic applications, concentrations are usually 10-50 times lower. BAC is one of the 
typical preservative systems used in ophthalmic solutions [16-17]. Is more active against 
bacteria but is weak against mold and is more active above a pH of 6 [18]. The 
homologues do not posses identical bactericidal activity. In general, the C I2 homologue is 
most effective against yeast and fungi, the CJ4 homologue against gram-positive bacteria, 
and the C16 homologue against gram-negative bacteria [19-20]. 
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Figure 1: Chemical structure of benzalkonium chloride (BAC), with "n" representing different alkyl chain 
lengths_ Major portion of the BAC comprising by a mixture of alkyl chains with length of n-CI2, n-CI4 , and 
C16­
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Recently, benzalkonium chloride was proven to enhance the antibacterial efficacy 
of antibiotics such as gatifloxacin [21]. Many analytical methods (HPLC and HPCE) 
were developed to determine BAC in a variety of products [16, 19-20, 22-26]. However, 
the described methods did not examine the fast separation of BAC homologues and their 
applicability might limited to a specific ophthalmic solutions. In some instances, due to 
the low conj:entrations of BAC, a salting-out technique was employed with the sum of all 
the homologues that might be present [16]. 
In this work we describe a new method for the analysis of the benzalkonium 
chloride in ophthalmic solutions. This represents an improvement over the current USP 
method for total BAC, which involves a titration [27]. The new method is a stability 
indicating method, its applicability was tested in different ophthalmic solutions and 
successfully validated based on International Conference on Harmonization guidelines 
[28]. 
2.2 Experimental 
2.2.1 Reagents and Chemicals 
The raw material for BAC (Century Pharmaceuticals, Indianapolis, USA) was 
provided by the product development group. ACS reagent sodium acetate trihydrate and 
reagent grade glacial acetic acid were purchased from Sigma Aldrich (Saint Louis, 
Missouri, USA). HPLC grade methanol was purchased by J.T. Baker (Phillipsburg, NJ, 
USA). 
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2.2.2 Equipment 
The Waters Alliance HPLC system (Waters Corporation, Milford, Massachusetts, 
USA) was used for the method development and method validation. The Alliance liquid 
chromatography system was equipped with 2695 separation module, 2487 UV detector 
and 996 photo diode array detector. Data collection and processing was done using the 
Empower chromatographic data acquisition system. 
2.2.3 Chromatographic Conditions 
A simple isocratic high performance liquid chromatography (HPLC) method was 
developed for the determination of benzalkonium chloride (BAC) in ophthalmic solutions. 
The chromatographic column used was a YMC, CN, 5 Ilm, 150 mm x 4.6 mm. The flow 
was kept at 1.0 mUmin during the length of the run and the column temperature was 
40°C. The wavelength was 262 nm and the injection volume was 100 ilL. The mobile 
phase utilized was 35:65 of 0.075 M sodium acetate trihydrate buffer with pH value 
adjusted to 5.0 with acetic acid: methanol. 
2.2.4 Testing Parameters 
Testing of the chromatographic method was performed in accordance to 
International Conference on Harmonisation (ICH) guidelines [28J and typical operating 
procedures for pharmaceutical analysis. The test parameters will be discussed in the same 
order as they were investigated during the method validation. 
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2.2.4.1 Specificity 
The specificity is the ability of the method to measure accurately and specifically 
the analytes in the presence of components that may be present in the sample matrix. In 
order to measure the degree of interference, ophthalmic samples, placebos, and standards 
of BAC were exposed to stress conditions of acid, base, peroxide, light and heat. 
Subsequently, the solutions were analyzed according to the chromatographic parameters 
presented in this paper to ensure no extraneous peak coeluted with the multicomponent 
BAC peaks. A UV diode array detector was used to check a 3-dimensional spectrum. 
2.2.4.2 Accuracy 
In order to measure the exactness of the analytical method between the true value 
and an accepted reference value, we spiked an ophthalmic solution without benzalkonium 
chloride (BAC) with BAC standard at three working levels 70%, 100%, and 130% of the 
theoretical concentration. Six preparations were performed at each level and assayed as 
per method conditions. The average result from each individual level was compared to its 
respective theoretical concentration value to check for any potential bias. All three 
average values were not significantly lower or higher than the theoretical value e.g. 
±1.5%. 
2.2.4.3 Linearity 
In order to show that there is a direct proportional relationship between the 
analyte response and its concentration, five concentration level solutions of BAC, 
corresponding from 50-150% of theoretical concentration were prepared and injected. In 
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addition, the ability of the system to retain and carryover the analyte into subsequent 
injections was evaluated by injecting a blank solution (diluent only) in duplicate 
immediately after the 150% linearity level. 
2.2.4.4 System Peiformance \ 
In order to ensure performance of the system before and during the analysis, 
system performance parameters, as defined in USPINF, [29] were established as a direct 
result of ruggedness and robustness experiments. 
2.2.4.5 Precision 
2.2.4.5.1 System Precision: We determined the system precision using six replicate 
measurements of a 100% theoretical standard solution containing benzalkonium chloride. 
The error contributed by the system, independent of the sample preparation, should be 
less than the acceptance criteria of 2.0 %. 
2.2.4.5.2 Repeatability: The repeatability, which is the error contributed by sample 
preparation, was determined by six identical sample preparations of the same sample. 
2.2.4.5.3 Intermediate: In order to evaluate the degree of agreement among test results 
obtained from multiple samplings of the same lot of samples on a different day using 
different instrument, column and analyst, six identical sample preparations of the same 
sample were used. 
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2.2.4.6 Robustness 
2.2.4.6.1 Chromatographic parameters: Robustness of a method is a measure of its 
capacity to remain unaffected by small but deliberate variations in chromatographic 
parameters. The parameters under test were wavelength, flow, colul!ln temperature, 
mobile phase ratio, and pH of the buffer in the mobile phase. These parameters were 
changed one at a time. System suitability and samples run were conducted with 
unchanged method parameters and modified parameters. 
2.2.4.6.2 Solution Stability: Standard and sample solutions were stored at room 
temperature and tested at initial, 48 hrs and 144 hrs. The solutions were tested against a 
freshly prepared standard at each time point. 
2.3 Results and Discussion 
2.3.1 Developmental Work 
There are many factors to consider when developing methods. One of the factors 
is the choice of the proper detection scheme which depends on the analyte's properties. 
UV detection was selected since benzalkonium chloride has an intense chromophore 
absorbing in the UV. The selection of the wavelength in our method (A=262 nm) was 
made based on a second maximum absorbance of BAC. More specific benzalkonium 
chloride has two UV maxima at about 210 nm and 262 nm. The second maximum is 
weaker but serves well with the selected mobile phase of methanol : sodium acetate 
trihydrate (65:35) since baseline noise was observed at wavelength around 210 nm. In 
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addition, the 262 nm wavelength was selected because methanol has a cutoff wavelength 
of 205 nm. 
Ideally for method development of new compounds with reversed phase HPLC 
several columns should be screened based on the pH tolerance. However, BAC is a 
mixture of well defined molecules and for that reason only one column was used during 
the method development. Different HPLC methods were reported in the literature for the 
analysis of benzalkonium chloride using reversed phase chromatography [30-34]. Due to 
its multicomponentnature and its low concentration in ophthalmic solutions (50-100 
ppm), BAC is a difficult material to analyze. The method should be quantitative. and 
qualitative in order to identify and distinguish the homologue components from each 
other and from other excipients. As a result, due to the low concentration of BAC and 
the fact that different formulations contain different sources of raw material which have 
different homo10gues made the method development very challenging. Several 
formulations with different homologues and different amounts of BAC were obtained and 
analyzed with the current method. The method appears to be suitable for these types of 
formulations. Figure 2 shows an overlay chromatogram of several different ophthalmic 
formulations containing the Cu, CI4, Cl6 and small amount of CIS BAC homologues. 
In the isocratic method, constant eluent composition in the column implies that 
equilibrium was established in the column and components moving through the column 
with constant velocity. Many attempts were made to elute all BAC homologues with 
gradient mobile phases but poor resolution between the BAC homologues and poor 
applicability between: different formulations made the method impractical. 
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Figure 2: Overlay chromatogram of several different ophthalmic formulations that contain Cl6 and CIS of 
benzalkonium chloride (SAC) homologues. SAC comprises primarily by a mixture of alkyl chains with 
length of Cl2• C14• and C16• 
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Since benzalkonium chloride is known for its adsorption in membrane material [17], a 
filter membrane (PTFE) was tested from two different vendors to evaluate the need of 
filtering solutions during the sample preparation. PTFE filters with dimensions of 25 mm 
and 0.45 !-tm porosity were tested. Results were compared against a non filtered sample. 
No significant change was observed between the vendors and filtered vs. unfiltered 
samples. 
System performance parameters were selected to provide confidence that the 
method is capable of determining BAC in ophthalmic solutions. A typical chromatogram 
for the benzalkonium chloride system performance standard solution is shown in Figure 3. 
The selected parameters include injection precision, resolution between C12, C l4 and C14, 
C16 homologues (when applicable), and a tailing factor of BAC homologues (CI2, C14, 
CI6). In addition, check standard conformity and bracketing standard conformity were 
proved during each chromatographic run. 
2.3.2 Experimental Work 
The specificity of the method was tested and no interference was observed for the 
. BAC peaks from forced degradation samples and ophthalmic solutions without BAC. 
During these studies equivalent amounts as per method of ophthalmic solution samples 
with and without BAC, BAC standard were stressed for the following conditions: (1) heat 
at 7SOC for 1 hr; (2) 5 mL of 1 N hydrochloric acid at 75°C for 1 hr; (3) 5 mL of 1 N 
sodium hydroxide at 75°C for 1 hr; (4) 5 mL of 30% hydrogen peroxide at 75°C for I hr; 
and (5) light exposure for 24 hrs as per ICH option 1. 
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(a) (b) 
Figure 3: System performance chromatogram (a): Full scale chromatogram (b): Expanded chromatogram. 
Performance parameters such as injection precision, resolution between the homologues, and tailing factor 
are evaluated. 
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Target 
Concentration 
Level 
Concentration 
(pg/mL) 
Response 
(Area) 
20% 9.95 58175.46 
50% 24.88 149170.44 
100% 49.77 296918.96 
120% 59.72 359065.31 
160% 79.62 480266.94 
Slope 6047756.17 
Y Intercept (% ) -2147.48 
Correlation 0.99995 
Table 1: Linearity parameters of benzalkonium chloride. Benzalkonium chloride found to have a linear 
response over a range of 20%-160% of theoretical concentration 0.05 mg/mL. 
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I The repeatability of the method was evaluated by SIX identical sample 
I 
t preparations of a homogeneous batch and the results were found to be within the 
specifications. The percent relative standard deviation of the six preparations for BAC 
was found to be 0.7%. 
1 
In order to further validate our results, the experiment was conducted again on 
i 
1 

different day by a different analyst, using different instruments, and different columns. 

I " The experimental mean agreement between the two experiments was found to be 0.4, 
.
i 
~ 
both experimental results were within the acceptance criteria. Results are displayed on 
I Table 2b. 
i 
The accuracy of the method was established by assaying three different BAC 
1 
i concentration levels 70%, 100%, and 130% of the theoretical concentration (0.05mglmL). i! 
1 
1 Six preparations of ophthalmic solutions without benzalkonium chloride, at each level, 
1 
.l were spiked with standard BAC and injected into the HPLC system. Results are reported 
I 
i in Table 2c with BAC mean recovery values varied from 99.2 to 99.5 % LC. No bias was 
observed for BAC, since the results for the mean recovery from all three accuracy levels 
were not significantly lower or higher (±1.5%) than the theoretical value. The range in 
which the method is shown to be linear and accurate for benzalkonium chloride is 
between 70-130% of theoretical concentration (0.05 mg/mL). 
The method remained unaffected by small, deliberate variations in 
chromatographic parameters and mobile phase preparation. The parameters tested were 
wavelength, flow, temperature, mobile phase ratio, and pH of the buffer. Table 3 shows 
the results of the small deliberately variations of the method conditions. 
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l 
Replicate # Peak Response (Area) i 
1 
2 
302895.88 
296933.32 
3 298289.29 
4 298556.27 
5 298255.89 
6 298355.70 
Mean 298881.06 
%RSD 0.7 
(a) 
Replicate 
% Label Claim (O/OLC) 
Benzalkonium Chloride 
Experiment 1 Experiment 2 
1 99.5 100.4 
2 101.0 101.3 
3 101.2 100.3 
4 99.5 101.6 
5 100.8 100.8 
6 101.5 101.8 
Mean 100.6 101.0 
%RSD 0.8 0.6 
Mean Agreement 0.4 
(b) 
Preparation # 
BAC 
Mean Recovery Value %LC 
70% Level 100% Level 130% Level 
1 99.4 99.4 98.9 
2 99.2 99.1 99.3 
3 99.2 99.4 99.6 
4 99.3 99.4 99.6 
5 99.1 99.7 99.7 
6 98.9 100.1 99.4 
Mean 99.2 99.5 99.4 
O/ORSD 0.2 0.3 0.3 
(c) 
Table 2: Experimental data of (a) System precision results, (b) Intermediate method precision results, (c) 
Accuracy results (ophthalmic solution spiked with BAC at three levels, 70, 100, 130% of theoretical) 
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Parameter Percent Comment 
Changed Difference (%LC) 
No Change (65:35), pH-5.0 N/A 98.5 
Wavelength 260 nm 0.5 99.0 
i 
i Wavelength 264 nm 0.4 98.9 
Column Temperature 38°C 0.3 98.8 
I 
Column Temperature 42 °C 0.7 99.2 i 
Flow 0.9 mLlmin 1.1 99.6 i 
Flow 1.1 mUmin 1.3 99.8 
• Mobile phase ratio (60:40), pH-5.0 1.4 99.9 
Mobile phase ratio (70:30), pH-5.0 0.7 99.2 
i Mobile phase pH:4.8, (65:35) 0.7 99.2 
Mobile phase pH=5.2, (65:35) 0.4 98.9 
I 
Table 3: Robustness results. Parameters which evaluated were wavelength, flow, column, mobile phase 
ratio and mobile phase pH. 
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The robustness results were within acceptance criteria of ±3.0 %LC, however some 
parameters are more critical than others. More specific the mobile phase ratio at 60:40 is 
critical to the shape of the BAC homologues and tailing factor (Tf) did not meet 
suitability criteria as per the method. The results variations that were observed between 
the normal method conditions and the changed parameters were from 0.3% to 1.4%. 
Critical parameters of the method such as mobile phase ratio, pH, and buffer 
concentration were evaluated and the results followed normal trends for reversed phase 
chromatography for cationic compounds. Figure 6 shows overlay chromatograms of 
mobile phase ratio, pH and buffer concentration. 
The stability of the standard and sample solutions for BAC was evaluated. The 
results are displayed on Table 4 and show no significant decrease over a period of 240 hrs 
for BAC in standard and 72 hrs for BAC in sample. 
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Figure 6: Robustness overlay chromatograms of critical method parameters: (a): organic:buffer ratio 
(b): pH and (C): buffer concentration 
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1 
j 
Benzalkonium Chloride in Standard 
Time Point 
Response % Difference from Initial 
Initial 100.0 N/A 
24 Hours 100.7 0.7 
72 Hours 101.9 1.9 
144 Hours 102.0 2.0 
Time Point Benzalkonium Chloride in Sample 
Response % Difference from Initial 
Initial 96.8 N/A 
24 Hours 97.6 0.8 
48 Hours 98.6 1.8 
Table 4: Solution stability results for BAC in standard and sample solutions. Standard solution was stable 
over a period of six days and sample solution was stable over a period of two days. 
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2.4 Conclusion 
The importance of preservatives in over the counter ophthalmic solutions is well 
known given the environment in which these solutions are kept. Often, users store the 
multidose bottles in medicine cabinets. purses, and pockets. exposed to extreme 
conditions of heat and humidity, all of which provide a good environment for microbial 
growth. Benzalkonium chloride is by far the preservative system of choice in ophthalmic 
solutions. In this chapter a new method for the determination of total benzalkonium 
chloride in ophthalmic solutions is described. The method separates the BAC 
homologues from each other and from other formulation components. The homologue 
separation is dependent to mobile phase ratio, pH and buffer strength. The testing for this 
method was performed according to ICH guidelines and met all acceptance criteria. Our 
experimental results indicated that the method is precise, accurate, and linear at 
concentration ranges of 0.035 mg/mL to 0.065 mglmL for total BAC. The analytical 
procedure is simple. fast, isocratic based on reversed phase chromatography (RPC) and 
applicable to a variety of ophthalmic solutions with BAC from different vendors. 
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Chapter 3: Demulcents (Polyvinylpyrrolidone) 
3.1 Introduction 
Lubricants, or demulcents, are often present in ophthalmic solutions and are used 
to control the solution viscosity. Additionally, they offer a medicinal benefit, relieving 
pain in inflamed or irritated mucous membranes. There are several demulcents in use in 
ophthalmic solutions, with selection done based on excipient compatibility, viscosity and 
the intent of medicinal benefit. In this study, several demulcents were studied: 
polyvinylpyrrolidone (PVP) , polyethylene glycol-400 (PEG-400) and glycerin. Since 
PVP and PEG400 are polymeric, size exclusion chromatography (SEC) is the technique 
of choice, however, most SEC methods focus on molecular weight characterization rather 
than quantitative analysis. In this work, total PVP in ophthalmic solutions was 
determined using the unusual combination of size exclusion chromatography, ultraviolet­
visible detection and quantitation of an analyte peak that elutes before the void volume 
disturbance [35]. A more conventional size exclusion chromatography method was used 
for the simultaneous determination of PEG400 and glycerin in ophthalmic solutions, 
using size exclusion chromatography, with refractive index detection [36], described in 
Chapter 4. 
Povidone (Polyvinylpyrrolidone, PVP) is a chain polymer of I-vinyl-2­
pyrrolidone, developed in the late 1930's [37]. PVP is obtained by a multistep synthesis 
that concludes by polymerization of vinylpyrrolidone in aqueous solution in the presence 
of hydrogen peroxide [38]. A wide range of molecular weights, from a few thousand to a 
few million Daltons can be obtained by controlling the degree of polymerization. PVP is 
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a white hygroscopic powder and unlike many synthetic polymers is soluble in a variety of 
traditional solvents such as water, chlorinated hydrocarbons, alcohols, arnides, and 
amines [39]. In our studies, PVP with a molecular weight of about 50,000 with a K-value 
of 30, typical in ophthalmic solutions, were used [40]. Figure 7 shows the structure of 
polyvinylpyrrolidone. 
PVP originally was used as a plasma substitute and in a variety of applications. Its 
hygroscopic properties, film formation, and adhesion to different materials have made 
PVP widely used in pharmaceuticals, cosmetics and industrial production. The 
interactions between the carbonyl groups in PVP and the hydroxyl group in polyphenols 
are well known and have been reported in the literature. Due to these interactions PVP is 
used to isolate polyphenols and as a colloidal stabilizer in beers by selective removal of 
i tannoid polyphenols [41-42], PVP formulations have been used to produce desired 
I solution viscosity, allowing the deposition of a uniform coating thickness of a photoresist 
in the manufacture of high resolution display screens [43]. In ophthalmic solutions, PVP 
is used as a demulcent or moisturizer and is generally present at approximately 1 % 
concentration in an aqueous matrix also containing other excipients and active 
formulation components. It has been shown in combination with polyethylene glycol 400 
and dextran 70 to be effective for the temporary relief of minor irritations, for protection 
of the eye against further irritation from the wind or sun and relief from eye dryness [44]. 
Many chromatographic methods have been reported in the literature for the 
determination of PVP, either qualitative determination of the molecular weight range of 
the polymer or quantitative determination in formulations and products, with most 
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IUPAC name: Polyvinylpyrrolidone 

Molecular formula: (C6H9NO)n 

Formula weight: 35000-51000 

Figure 7: Structure of polyvinylpyrrolidone 
35 

focusing on the qualitative aspects such as the form of polyvinylpyrrolidone present and 
whether materials with same K-value are structurally the same [45-46J, 
A variety of capillary electrophoresis (CE) methods for the characterization and 
determination of povidone have been reported, including capillary zone electrophoresis 
(CZE) and capillary gel electrophoresis (CGE) [47-50]. Polyvinylpyrrolidone has been 
determined in several pharmaceutical matrices with solid phase microextraction and GC. 
The fibers were polypyrrole (PPy) and desorption was performed at the inlet of gas 
chromatograph equipped with a nitrogen phosphorous detector [51J. PVP has also been 
used as stationary phase materials or extractant [52-55]. SEC determinations of 
polyvinylpyrrolidone have focused on molecular weight characterization of the 
polyvinylpyrrolidone itself or the use of polyvinylpyrrolidone as a molecular weight 
calibrator for other determinations [56-64], 
SEC is not usually used in combination with UV detection, however it is clearly 
applicable if the analytes and other compounds of interest in the analytical samples 
contain a chromophore. Some pharmaceutical applications of SEC with UV detection 
include a recent study of the mass balance in the oxidative degradation of rapamycin and 
the analysis of various proteins and biological polymers in formulations [65-67]. 
Determination of total PVP present in the matrix of a pharmaceutical formulation using 
SEC and UV detection has not been previously reported. In this work we describe a fast, 
straightforward new HPLC method for the analysis of total PVP in ophthalmic solutions. 
The new method is stability indicating and was successfully validated based on the 
International Conference on Harmonization guidelines for pharmaceutical quality 
assurance [68], 
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3.2 Experimental 
3.2.1 Reagents and Chemicals 
The raw material for PVP was purchased from BASF AG (Ludwigshafen, 
Germany). HPLC grade methanol was obtained from Fisher Scientific Inc. (Fairlawn, 
New Jersey, USA). ACS reagent grade sodium acetate was purchased from Sigma 
Aldrich (Saint Louis, Missouri, USA). Water was obtained using a Milli-Q (Millipore, 
Milford, MA) purification system located in our laboratory. 
Laboratory formulations of typical opthalmic solutions were prepared in water at 
0.5 mg/mL concentration of povidone. There were diluted by adding 10 mL of 
formulation to a 50 mL volumetric flask and diluting to the mark with water prior to 
HPLC analysis. The final working concentration of the sample and standard solutions 
was 0.1 mg/mL. 
3.2.2 Instrumental Conditions 
An Alliance HPLC system equipped with a 2695 separation module with 2487 
UV and 996 photodiode array detectors was used for all experiments. Data collection 
and processing was performed using an Empower chromatographic data acquisition 
system. (Waters Corporation, Milford, Massachusetts, USA) The chromatographic 
column was a TSKgel G1000PW, 7.5 mm ID x 30 cm, 12 !lm column (TOSOH 
Bioscience, Tokyo, Japan). The flow was kept at 1.0 mLimin during the length of the run 
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and the column temperature was 50°C. The UV detector wavelength was 220 nm and the 
injection volume was 25 JlL. The mobile phase was premixed 800 mL 0.1 M sodium 
acetate and 200 mL methanol generating a mobile phase pH of about 10. 
3.2.3 Testing Parameters 
Testing of the chromatographic method was performed in accordance with ICH 
guidelines and typical operating procedures for pharmaceutical analysis. The test 
parameters are presented in the same order as they were investigated during the method 
validation. Specificity was determined by exposing ophthalmic solution samples with and 
without polyvinylpyrrolidone, and polyvinylpyrrolidone standards to stress conditions of 
acid, base, hydrogen peroxide, light and heat and subsequently analyzing them according 
to the method. A photodiode array detector was used during validation to ensure that no 
interfering compounds co-eluted with PVP but is not necessary for the final method. 
Accuracy was measured by spiking with PVP ophthalmic solutions without PVP at three 
working levels 0.35, 0.50 and 0.80 mg/mL (70%, 100%, and 130% of the standard 
concentration). Six preparations were performed at each level and assayed as per method 
conditions. The average result from each individual level was compared to its respective 
theoretical concentration value to check for any potential bias. 
To ensure that the method is linear in the working concentration range, five 
concentration level solutions of polyvinylpyrrolidone, corresponding from 0.25-0.75 
mglmL (50-150% of the expected analyte concentration) were prepared and injected. In 
addition, the ability of the system to retain and carryover the analyte into subsequent 
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injections were evaluated by injecting a blank solution (diluent only) in duplicate 
immediately after the 150% linearity level. To ensure performance of the system before 
and during the analysis, system performance parameters, as defined in the USPINF, were 
established as a direct result of ruggedness and robustness experiments [69]. 
System precision was determined using six replicate measurements of a 100% 
theoretical concentration standard solution (0.5 mg/mL PVP concentration) containing 
polyvinylpyrrolidone, with an acceptance criterion of the RSD being less than 2.0%. 
Repeatability was determined by six identical sample preparations of the same lot. To 
determine agreement among test results obtained from multiple samplings of the same lot 
of samples on different days using different instruments, columns and analysts, six 
identical samples from the same lot were prepared and analyzed. 
Robustness was determined by examining small variations in: wavelength (±4 
nm), flow rate (±0.1 mUmin), column temperature (±5°C), and mobile phase preparation 
(±1O%). These parameters were changed one at a time. System performance and sample 
runs were both conducted with unchanged method parameters and modified parameters. 
In addition a quantitative comparison study was performed between the raw material that 
was used to prepare the batch and other raw materials of polyvinylpyrrolidone including 
a USP reference standard. One sample preparation was run and quantitated with five 
different standards as per the method. Further, to assess sample stability, standard and 
sample solutions were stored at room temperature and tested at initial, 24 hrs, 96 hrs, and 
192 hrs. The solutions were tested against a freshly prepared standard at each time point. 
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3.3 Results and Discussion 
3.3.1 Developmental Work 
The physical and chemical properties of polyvinylpyrrolidone have been well 
established, since its discovery in 1930 [37-40]. UV detection was selected for this work 
since PVP has a chromophore in the ultraviolet range, with a maximum at 213.5 nm. The 
UV spectrum of PVP is shown in Figure 8. In the final method, 220 nm was selected for 
the UV detector wavelength. During method development. excessive noise. possibly 
from the solvent (methanol has a UV cutoff of 205 nm) or impurities in the solvents 
precluded the use of 213.5 nm. No deleterious quantitative effects from detecting PVP 
on the slope of the UV spectrum rather than the maximum were observed. Although the 
UV detector is possibly the most versatile and useful detector in high performance liquid 
chromatography, it is not as widely used in SEC since many polymers do not absorb 
electromagnetic radiation in the UV range. Other detectors such as refractive index or 
light scattering are more commonly used, but quantitation and method validation are 
often challenging with these [70]. Thus the combination of SEC with UV detection is 
especially suited to this application and would be suitable for other polymer analysis in 
which a chromophore is present. Figure 8 shows a UV spectrum of povidone with a 
maximum absorbance about 213 nm. 
The main goal during method development was to have an isocratic method that 
separates PVP from other compounds in the formulation or degradation products. 
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Figure 8: UV spectrum of polyvinylpyrrolidone with a UV maximum absorbance at 213 nm. 
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Usually in SEC method development for unknowns, the molecular weight of the analyte 
polymer must be independently determined to aid in column selection. In this study that 
was not necessary since the molecular weight range of PVP, approximately 50 kDa, was 
provided by the vendor. Initially, several size exclusion columns from different 
manufacturers were screened and TSK-gel GlO00PW, 7.5 mm ID x 30 cm x 12; !!m 
column was selected based on symmetrical peak: shape of PVP. TSK-gel columns in 
general consist of hydrophilic polymethacrylate spherical beads with sizes ranging from 
12 !!m to 17 !!m. These types of columns are suitable for the analysis of water soluble 
polymers and more specific the Gl000PW is suitable for small (1000 Da and less) 
molecular weight polymers. As seen in Figure 9, in our method the TSK-ge1 GlOOOPW 
column is used in a reversed context: the analyte is of much higher molecular weight than 
would normally be separated by this column, eluting before the void volume disturbance, 
fully excluded from the stationary phase. Other compounds present, with molecular 
weights less than 1000, elute in the separation range of the column. While uncommon, 
quantifying a peak: eluting before the void volume has been recently reported in a similar 
context for the group assay of polyvinylsulfonic acid impurities in 2-(Nomorpholino)­
ethanesulfonic acid [71]. Figure 9 clearly shows a very symmetrical peak: for PVP, 
demonstrating a satisfactory tailing factor for system performance and the validation data 
presented in the next section demonstrate adequate precision. The symmetrical peak: of 
polyvinylpyrrolidone is expected based on the exclusion of the molecule from the porous 
space of packing material and its fast elution from the column. 
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(a) (b) 
Figure 9: Chromatogram of polyvinylpyrrolidone (a): Full scale chromatogram (b): Expanded 
chromatogram 
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SEC separation is based on molecular size of the analyte relative to the pore size 
of the packing material. Mobile phase selection is important to avoid enthalpic 
interactions between the analyte and the packing material. There are a variety of solvents 
compatible with TSK-GEL columns, so the selection process depends on the chemical 
structure and ionic nature of the analyte. In this study since a UV detector was used the 
ideal mobile phase should have a low UV absorbance as well. Methanol has a low 
wavelength UV absorbance cutoff of about 205 nm and low background absorbance 
combined with good solubilizing properties for polyvinylpyrrolidone made methanol the 
organic solvent of choice for this method. For simplicity, premixed aqueous buffer 
mixture of 0.1 M sodium acetate with methanol (80:20% v:v) was selected as the mobile 
phase [72]. This generates a mobile phase pH of approximately 10, which assists in 
ensuring rapid and efficient transport of PVP through the column by ensuring that the 
electron pair on nitrogen in PVP does not protonate while the hydroxyl groups on the 
surface of the TSK-GEL column are slightly deprotonated, generating additional 
repulsion between the stationary phase and the analyte. 
Temperature adjustment can reduce the analysis time and improve 
chromatographic performance. More specific as the temperature increases, the viscosity 
of the mobile phase decreases and the diffusivity of the analyte increases. Fast size 
exclusion chromatography has been discussed in the literature and temperature is one of 
the primary parameters adjusted to achieve faster analysis times [73-74]. Optimum 
chromatographic performance was obtained in this method with column temperature at 
50°C. 
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3.3.2 Experimental Work 
Figure 10 shows the analysis of PVP in a formulation (top), standard (middle) and 
formulation without PVP (bottom). PVP does not appear in the placebo which is simply 
a formulation prepared without the analyte, demonstrating that compounds other 
compounds that commonly appear in ophthalmic formulations will not interfere with the 
method. This chromatogram clearly demonstrates the reverse SEC analysis: determining 
a larger molecular weight compound using a column designed for small molecular weight 
analytes. PVP elutes first, followed by the void volume disturbance, followed by other 
components. In each case, chromatographic performance, was evaluated by tailing factor, 
peak shape, peak width, and found to be adequate. 
Figure lla shows chromatograms of several PVP polymer formulations in 
combination with a vinyl pyrollidone monomer. In these chromatograms, the PVP 
polymer is seen eluting before the void volume of the column (totally excluded from the 
stationary phase pores) and the monomer eluting within the analytical range of the 
column. Further, all of the polymer formulations elute at the same retention time in the 
void volume, providing the desired total analysis from a single chromatographic peak, 
regardless of variations in the polymer formulation. Essentially all material with a 
molecular weight greater than 1000 Da is included in the main peak. In Figure lIb, a 
chromatogram of the PVP used in this study for ophthalmic formulations in combination 
with its monomer is shown, demonstrating the outstanding selectivity of this system. 
The specificity of the method was tested and no interference was observed for the 
polyvinylpyrrolidone peak from ophthalmic solution without polyvinylpyrrolidone and 
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Figure 10: Overlay chromatogram of ophthalmic formulation (top), standard of polyvinylpyrrolidone 
(middle), and formulation without polyvinylpyrrolidone (bottom) 
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Figure 11: Overlay chromatogram of different molecular weight polyvinylpyrrolidone polymers (a) 
chromatogram of polyvinylpyrrolidone and its monomer 
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forced degradation samP.1es. To ensure no extraneous peak co-eluted with the peak of 
interest, a UV diode array detector was used to double check the full UV spectrum for all 
peaks. Figure 12 shows overlay chromatograms of the sample without 
polyvinylpyrrolidone (a) sample (b) and standard (c) at different stress conditions. 
Linearity of the method was established by injecting five standard concentrations 
of polyvinylpyrrolidone and preparing a calibration curve by plotting PVP response 
versus concentration. The solutions covered a concentration range of 0.05 - 0.15%. The 
linearity curve for polyvinylpyrrolidone is presented in Figure 13. The solutions covered 
a range of 50%-150 % of theoretical concentration 0.1 mg/mL. The method was linear in 
this range with R2 values of 0.9999. Concentration of linearity solutions, responses and 
linearity parameters such as slope, y-intercept, and coefficient of determination are listed 
in Table 5. No carryover was observed into blank injections immediately after the highest 
level linearity standard, ensuring independence of the samples. 
System precision was established by six replicate measurements of a 100% 
theoretical standard solution of povidone. The %RSD for povidone was found to be 0.1 %. 
Table 6a shows the results, mean and standard deviation. 
The repeatability of the method was evaluated by six identical sample 
preparations of a homogeneous batch and the results were found to be within the 
specifications. The percent relative standard deviation of the six preparations for 
polyvinylpyrrolidone was found to be 0.3%. In order to further validate the results, the 
experiment was conducted again on a different day using a different instrument, column 
and analyst. In addition the work was repeated at a different work site, using different 
instruments and different columns. 
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Figure 12: Overlay stress studies chromatograms for (a) ophthalmic solution without polyvinylpyrrolidone 
(b) ophthalmic solution (C) polyvinylpyrrolidone standard 
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Linearity of Polyvinylpyrrolidone 

y =6,216, 701.63197x· 6,4 70.92235 
1,200,000 R~ =0.9999S 
1,000,000 

800,000 
 /
«I 
t! 600,000
« • Polyvinvlpyrrolidone 
-linear (Polyvinylpyrrolidone)400,000 
./
100,000 
0 I 
0.00 0.05 0.10 O.l~ 0.20 
Concentration mg/ml 
Figure 13: Linearity graph of Polyvinylpyrrolidone (PVP). PVP found to has a linear response over a range 
of 50%-150% of theoretical concentration 0.1 mg/mL 
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Target 
Concentration 
Level 
Concentration 
(mglmL) 
Response 
(Peak Area) 
50% 0.05225 320089.74 
80% 0.083600 512627.13 
100% 0.104500 640589.55 
130% 0.135850 838004.55 
150% 0.156760 969587.72 
Slope 62616701.63 
Y Intercept (%) ·6470.92 
Correlation 0.99995 
Table 5: Linearity parameters of polyvinylpyrrolidone (PVP). PVP found to has a linear response over a 
range of 50%-150% of theoretical concentration 0.1 mglmL 
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Replicate # Peak Response (Area) 
1 601997.31 
2 601504.28 
3 601485.97 
4 600671.02 
5 601882.20 
6 601477.17 
Mean 601502.99 
%RSD 0.1 I 
(a) 
Replicate 
% Label Claim of Povidone (%LC) 
Intermediate Precision Reproducibility 
Analyst llLab 1 Analyst 2ILab 1 Lab 1 Lab 2 
1 102.0 102.0 102.0 102.4 
2 102.3 101.9 102.3 102.9 
3 102.4 102.1 102.4 102.9 
4 102.8 103.3 102.8 103.1 
5 101.9 101.4 101.9 102.7 
6 102.6 102.7 102.6 102.8 
. Mean 102.3 102.2 102.3 102.8 
%RSD 0.3 0.7 0.3 0.2 
Mean Agreement 0.1 0.5 
(b) 
Table 6: Experimental results for (a) system precision and (b) intermediate method precision and 
reproducibility results 
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The experimental mean agreement for povidone between the two days and sites was 
found to be 0.1 and 0.5 respectively and is within the acceptance criteria. Results are 
displayed in Table 6b. 
The accuracy of the method was established by assaymg three different 
concentration levels 70%, 100%, and 130% ofthe theoretical concentration. 
Six preparations of ophthalmic formulation without polyvinylpyrrolidone, at each level, 
were spiked with standard of polyvinylpyrrolidone and were injected into the HPLC 
system. Results are reported in Table 7a with polyvinylpyrrolidone mean recovery values 
varied from 100.0 to 100.8% of the prepared standard concentration. No bias was 
observed for polyvinylpyrrolidone, since the results for the mean recovery from all three 
accuracy levels were not significantly lower or higher (±l.S%) than the theoretical value. 
The range in which the method is shown to be linear and accurate for povidone is 
between 70-130% of theoretical concentration. 
The method was unaffected by small, deliberate variations in chromatographic 
parameters and mobile phase preparation. The parameters tested were detector 
wavelength (+1- 4 nm), mobile phase flow rate (+1- 0.1 mL/min) and temperature (+1­
5°C). Retention time and the peak shape were not affected by these parameters. The 
variation in results that was observed between the normal method conditions and the 
changed parameters were from 0.1 to 1.6% for povidone. Table 7b shows the results that 
were obtained by the'robustness studies of polyvinylpyrrolidone. 
Different lots of polyvinylpyrrolidone raw materials were used to evaluate the 
impact on the assay values using polyvinylpyrrolidone other than the one used in the 
formulation batch. In addition, the USP reference standard of polyvinylpyrrolidone was 
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Pre # 
1 
2 
3 
4 
5 
6 
Mean 
%RSD 
(a) 
Parameters under study % LC of povidone Percent ditTerence 
Control 102.8 N/A 
Flow 0.9ml/rnin 103.6 -0.8 
Flow l.1ml/min 103.8 -1.0 
Column temperature 45· C 102.7 0.1 
Column temperature 55· C 103.1 -0.3 
Mobile Phase - 10% 103.5 -0.7 
Mobile Phase + 10% 104.4 -1.6 
Wavelength at 216nm 102.9 -0.7 
Wavelength at 224nm 103.6 -0.9 
(b) 
Table 7: Experimental results for (a) Accuracy results (Ophthalmic solution without polyvinylpyrrolidone 
spiked with standard solution of polyvinylpyrolidone at three levels, 70, 100, 130% of theoretical) and (b) 
robustness studies of polyvinylpyrolidone 
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evaluated to quantitate polyvinylpyrrolidone in ophthalmic solutions. One sample 
preparation was run with five different raw material polyvinylpyrrolidone standards and 
one USP reference standard as per method. Table 8a summarizes the results of this test. 
An attempt to explain the variability on the results the water content of each standard of 
polyvinylpyrrolidone was determined by Karl Fischer as per USP 30 <921> method I. 
It should be noted that standard 6 is the USP standard and water content was not 
performed for this standard because it was dried prior to its use. Table 8b summarizes the 
water content results of polyvinylpyrrolidone. The water content results explain the 
variability on the assay sample results that were observed when different standards were 
used. If results corrected for water content then they are a lot closer to each other and the 
differences between them are within experimental error of the analytical method. Table 
8c shows the results taking into account the water content. 
The stability of the standard and sample solutions for povidone was also evaluated. 
No significant change in PVP response was observed over a period of 192 hrs. Solutions 
stored at refrigerator and ambient temperature. Samples tested at the same time and 
results between the two conditions were comparable. Table 9 shows the solution stability 
of both standard and sample at ambient temperature. 
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I 
Standard 1 
Povidone 
Standard 2 
Povidone 
Standard 3 Standard 4 
Povidone Povidone 
% Label Claim 
Standard 5 
Povidone 
Standard 6 
Povidone 
Assay 
Absolute 
difference 
from 
102.7 
N/A 
106.8 
4.1 
i 106.4 
3.7 
105.1 
2.4 
107.0 
4.3 
101.3 
1.4 
Standard 1 I 
(a) 
Standard 5 
I Povidone 
Standard 1 Standard 2 
Povidone 
Standard 3 
Povidone 
Standard 4 
Povidone 
Standard 6 
Povidone Povidone 
% water content 
Water 
3.84 6.42 6.81 4.93 N/A*7.11 
content 

Absolute 

difference 

N/A N/A2.58 2.97 1.09 3.27 
from 

Standard 1 
 i I 
..
*Waler content of USP standard not determmed SInce It IS dned pnor to use 
(b) 
I Standard 1 Standard 2 Standard 3 Standard 4 Standard 5 I Standard 6 Povidone Povidone Povidone Povidone Povidone . Povidone 
i 
% Label Claim 
Assay 98.7 99.9 99.2 99.9 99.4 101.3 
Absolute 
difference N/A 1.2 0.5 1.2 0.7 2.6 
from ! 
Standard 1 I 
(c) 
Table 8: Evaluation of polyvinylpyrrolidone assay using different raw material (a) assay results of 
ophthalmic formulation using different raw materials of polyvinylpyrrolidone as a standard. (b) water 
content of polyvinylpyrrolidone standards, (c) assay results of ophthalmic formulation taking into account 
the water content of polyvinylpyrrolidone 
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Time Point 
Standard Sample 
I 
% Label Claim of polyvinylpyrrolidone (%LC) 
Initial 99.5 102.0 
24 Hours 99.9 10204 
4 Days 100.8 102.8 
8 days lOlA 104.3 
Table 9 Solution stability studies of polyvinylpyrrolidone at ambient temperature 
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3.4 Conclusion 
A new method for the determination of total polyvinylpyrrolidone in ophthalmic 
solutions was developed using SEC-UV with quantitation of the analyte peak eluting 
before the void volume disturbance. This unique combination separated 
polyvinylpyrrolidone from other formulation components and allowed a simple isocratic 
method. Validation for this method was performed according to ICH guidelines and met 
all acceptance criteria. The method is precise (+/- 0.1 %), accurate (+/- 1 %), and linear at 
concentration ranges of 0.07 mg/mL to 0.13 mg/mL, typical of prepared ophthalmic 
solution samples for polyvinylpyrrolidone. Several unusual chromatographic situations 
were used together successfully in this work: SEC with UV detection and quantitation of 
a chromatographic peak eluting before the void volume. This method provides a model 
for the analysis of a polymeric component in the presence of monomeric components in a 
number of different types of formulations. 
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Chapter 4: Demulcents (PEG400 and Glycerin) 
4.1 Introduction 
An array of over the counter (OTC) ophthalmic solutions is available for the 
self treatment of minor ophthalmic disorders. Common treatments for minor eye 
episodes include the use of OTC ophthalmic lubricants, including artificial tears 
products which contain polyethylene glycol 400, and glycerin. The use of lubricants 
offers many advantages. From a chemical composition perspective, they are used to 
control the viscosity of the solutions. They also offer a medicinal benefit: to relieve 
pain in inflamed or irritated mucous membranes. 
Glycerin was synthesized by the Swedish scientist K. W. Scheele in 1779, as a 
result of heating a mixture of olive oil with lead monoxide. He published this method in 
1783 after noticing other metals and glycerides produced the same chemical reaction 
which yields glycerin and soap. However, it was not until 1811 when the French 
investigator M. E. Chevreul discovered the immeasurable properties of glycerin. He 
named the compound glycerin after the Greek word glykys, meaning sweet. Twelve years 
later he patented a new way to produce fatty acids from fats when treated with alkali in 
which glycerin was released. The first empirical formula of glycerin (C3Hs03) wasI 
I 
, 
~ announced in 1835 by French investigator Pelouze. About fifty years later, in 1883, 
i Berthelot and Lucea established the accepted formula of glycerin C3Hs(OHh [75-76]. 
i 
:! 
:1 The unique chemical and physical properties of glycerin including that it is not 
1, 
l 
.1 toxic to the digestive system and not a skin irritant, make glycerin applicable in a variety 
I 
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of applications within the chemical, pharmaceutical, consumer, and food industries [77]. 
In ophthalmic solutions, glycerin is generally present at approximately 0.2% 
concentration in an aqueous matrix containing other formulation components and active 
therapeutic ingredients. Glycerin is also used as a lubricant to relieve symptoms of dry 
eyes such as burning, and itching, which are caused by exposure to wind, sun, heating, air 
conditioning, and extended computer use. 
Chemically, glycerin is a very stable alcohol. It has three hydroxyl groups which 
can react with other chemical groups, thereby permitting the synthesis of many different 
derivatives with specific applications [78]. Physically, glycerin is a clear and viscous 
liquid miscible with water and alcohol. At low temperature glycerin does not crystallize 
which makes it a favorable candidate for cooling systems such as antifreeze. However, 
the most important property of glycerin is its ability to absorb and hold moisture from the 
air. This unique property, in conjunction with a glycerin-water solution makes glycerin a 
suitable agent for plasticizers which give products the desired shelf life, flexibility and 
softness. Glycerin is found in nature in the form of triglycerides and occurs naturally in 
beers, wines, breads and other products of grains and sugars. 
As was mentioned above, glycerin has three hydroxyl groups. Two of these 
groups are primary and the other secondary [79]. Figure 14a shows the structure of 
glycerin. The two primary hydroxyl groups are more reactive than the secondary but in 
some reactions the secondary hydroxyl group can react before all the primary groups are 
exhausted. Industrially, glycerin is produced during saponification from fats and oils after 
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OH 

Structure name: propane-l,2,3-triol 
Molecular formula: C3Hg03 
Formula weight: 92.09 
(a) 
OH 
Structure name: Polyethylene Glycol 
Molecular formula: CnH4n+20n+l> n=8.2 to 9.1 
Formula weight: 380-420 
(b) 
Figure 14: Structures of a) Glycerin and b) PEG400 
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Hydrolysis. It is recovered in a crude state and purified by ion exchange or distillation 
[75]. 
Glycerin is analyzed with different techniques that are labor intensive and in 
many instances not stability indicating. A more specific assay of glycerin in the United 
States Pharmacopeia is accomplished by periodate oxidation titration. Glycerin is 
oxidized by potassium periodate to form fornUc acid, then the solution is titrated with 
standard potassium arsenite and the liberated iodine is indicated by the starch-iodine 
reaction [80]. 
Glycerin and its derivatives have been chromatographically analyzed by a variety 
of techniques including thin layer chromatography (TLC), gas chromatography (GC). 
capillary electrophoresis (CE). ion chromatography and HPLC utilizing different 
detectors. ultra violet (UV). charged aerosol detector (CAD) [81-86]. A large number of 
chromatographic methods for the determination of glycerin have been also reported in 
biodiesel research literature [87-102]. Biodiesel is a renewable fuel from natural oils like 
soybean oil. rapeseed oil or animal fats and produced by transesterification reaction of 
these oils/fats with alcohol to yield smaller molecules (FAMES). Their properties are 
close to diesel fuel. However. during this process glycerin also is generated as by-product 
of the reaction and needs to be removed because it can be harmful to the engine. There is 
a maximum amount of free and total glycerin that permitted in the fuel and is limited to 
0.02% and 0.24% respectively (0.25% for European) [103]. Figure 15 shows such a 
reaction. 
Glycerin is a metabolic precursor for the synthesis of triglycerides and membrane 
phospholipids. The serum content of glycerin is correlated as a marker of cardiovascular 
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H2C-OCOR1 R1COOCH3 H2C-OH 
Basic Catalyst I .. I 
HC-OCOR2 + 3CH3OH ... R2COOCH3 + HC-OH I I 

H2C-OCOR3 R3COOCH3 H2C-OH 
Biodiesel 
Vegetable Oil Methanol (FAME) Glycerin 
Figure 15: Transesterification reaction of triglycerides to fatty acid methyl esters [92] 
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disease [104] and the plasma, tissue content of glycerin is considered and index of 
cardiac triglyceride metabolism [105]. A significant number of publications exist in this 
area for the analysis of polyhydroxyl compounds using thin layer chromatography, [106­
107] enzyme linked assays, [108-109] pulsed amperometric detection, [110] mass spectra 
analysis [111-112] and UV detection [113-118]. 
Polyethylene glycol is a polyether compound with many applications to consumer 
and pharmaceutical products. Manufactured by the polymerization of ethylene oxide with 
either water, mono ethylene glycol or diethylene glycol under alkaline catalysis. Ethylene 
glycol and ethylene glycol oligomers are preferred over water because the products of 
such reactions are polymers with smaller range of molecular weight (low polydispersity) 
[119-120]. 
After the desired molecular weight was reached, the reaction is terminated by 
adding an acid to neutralize the catalyst. The molar mass distribution of polyethylene 
. glycol defines the different grades assigned for this chemical substance. The various 
grades of polyethylene glycols are not uniform compounds, but rather mixtures of similar 
polymer members. For that reason, controlling the polymerization is a very important 
step in the production of polyethylene glycol. Molar mass distribution is assigned by gel 
permeation chromatography (GPC) in which analysis is based on the different migration 
rates of the polymer mixture in microporous gel. In general, each polyethylene glycol 
follows by a number which is the average molecular weight of the polymer. 
Polyethylene glycol with the general formula H(OCH2CH3)nOH can be in both 
liquid or solid form based on the size of the molecular weight [121]. Structurally the 
shorter chains, (with a degree of polymerization less than 10) form a zigzag structure, 
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while the longer chains are in the crystalline state, form a twisting / spiral like structure 
where the oxygen atoms form ether bridges at regular intervals. Figure 14b shows the 
structure of PEG400. 
Chemically the hydroxyl end groups of polyethylene glycol have a significant role 
in the physical and chemical properties of these molecules and for that reason molecules 
of molecular weights 200-35000, are referenced as polyethylene glycols and not 
polyethylene oxides. 
Physically these molecules are clear, viscous liquids or white solids which 
dissolve in a variety of solvents including water to form transparent solutions. They are 
soluble in aromatic hydrocarbons and slightly soluble in aliphatic hydrocarbons. 
Polyethylene glycols are very stable molecules which do not hydrolyze or otherwise 
deteriorate upon storage and do not support mold growth. They are compounds of low 
toxicity and for that reason are widely applicable in many different industries [122]. In 
ophthalmic solutions, PEG400 is used as a moisturizer, and is generally present at 
approximately 1 % concentration in· an aqueous matrix containing other excipients and 
active pharmaceutical components. PEG400 is used to adjust the viscosity of the solution 
and to enhance the solubility of other poorly soluble components in the formulation. The 
formulation viscosity is a critical parameter in ophthalmic solutions because it enables the 
formulation to remain in the eye longer and gives more time for the drug to exert its 
therapeutic activity or undergo absorption. 
Smaller range molecular mass polyethylene glycols are used extensively in the 
pharmaceutical industry and in clinical research [123]. Therefore there are many 
requirements for accurate quality control and product characterization methods. It should 
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also be noted that chromatography is the preferred method for analyzing such compounds 
[124-132]. Other methods such as colorimetry, [133] turbidimetry, [134] Fourier 
Transform IR (FTIR) [135] can provide only bulk information about polyethylene glycols 
and are subject to interference. Paper chromatography methods have been used for the 
determination of polyethylene glycols but the method is limited in sensitivity and 
repeatability [136]. Capillary gel electrophoresis has also been reported in the literature 
for the separation of the polyethylene glycols but this method, too, has its limitations to 
column fragility and cost [137]. Derivatization techniques are widely used for the 
separation of polyethylene glycols due to the popularity of the conventional UV detector. 
These techniques also allow the use of fluorescent detectors, minimizing interference and 
increase the detection limits [138-140]. UV detection without using derivatisation was 
also reported in the literature but the use of sodium azide in the mobile phase was needed 
to minimize solvent absorbances of mobile phase components. However, the baseline 
drift still posed a problem [141]. An evaporative light scattering detector was 
successfully implemented in the determination of polyethylene glycols without· 
derivatization [142]. More expensive mass spectrometer detectors are not widely used 
and are not available to every laboratory have been used for the analysis of polyethylene 
glycols [143-145]. 
Based on extensive investigation of the literature no method appeared to report 
the simultaneous determination of PEG400 and glycerin in ophthalmic solutions. One 
paper was found for the determination of PEG400 in ophthalmic solution but it was using 
two different columns in series to separate PEG400 from other components in the 
formulation. It should be noted, that the method applicability in this work was limited to 
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a specific type of ophthalmic formulation and the length of each column used was 300 
mm which made the instrument arrangements a bit more complicated. In addition the 
mobile phase used in this publication was methanol and the buffer system consisted ofby 
. three different components, making the pre-run system preparation time consuming [146]. 
In this work a new method is described for the analysis of PEG400 and glycerin 
in ophthalmic solutions. The analytical procedure is a simple, direct HPLC method that is 
based on Size Exclusion Chromatography (SEC). The sample is diluted with water and 
injected into a HPLC instrument equipped with TOSOH Bioscience TSKgel GIOOOPW, 
7.5 mm ID x 30 cm, 10 Jlm column at 50°C. Quantitation is achieved by comparison of 
peak heights of PEG400 and glycerin in the sample to that of a known concentration 
reference standard. PEG400. and glycerin are separated from other components in the 
formula and detected by a Waters Refractive Index (RI) detector. 
4.2 Experimental 
4.2.1 Reagents and Chemicals 
The raw material for PEG400 was purchased from P&G Chemical (Cincinnati, 
OH, USA) and the raw material for glycerin was purchased from Clariant Produkte 
(Gendorf, Germany). HPLC water grade was purchased by J.T. Baker (Phillipsburg, NJ, 
USA). 
Laboratory formulations of typical opthalmic solutions were prepared in water at 
0.57 mg/mL and 0.13 mg/mL concentration of PEG400 and glycerin respectively. They 
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were diluted by adding 5 mL of formulation to a 100 mL volumetric flask and diluting to 
the mark with water prior to HPLC analysis. The standard working concentrations of the 
standard solutions were 0.57 mg/mL and 0.13 mg/mL for PEG400 and glycerin 
respectively. They were prepared by weighing 130 mg of glycerin into 50 mL volumetric 
flask and diluted to the mark with water (glycerin stock solution). Working standard 
concentrations were prepared by weighing 114mg of PEG400 into 200 mL volumetric 
flask and pipette 10 mL of glycerin stock mix well and diluted to the mark with water. 
The working standard concentrations were 0.57 mg/mL and 0.13 mg/mL for PEG400 and 
glycerin respectively. 
4.2.2 Instrumental Conditions 
An Alliance HPLC system equipped with a 2695 separation module with a 
differential refractive index detector model 4210 was used for all experiments. Data 
collection and processing was performed using an Empower chromatographic data 
acquisition system. (Waters Corporation, Milford, Massachusetts, USA) The 
chromatographic column was a TSKgel G2000PW, 7.5 mm ID x 30 cm, 12 J.lm column 
(TOSOH Bioscience, Tokyo, Japan). The flow was kept at 1.0 mLimin during the length 
of the run and the column temperature was 50°C. The refractive index detector settings 
were: sensitivity 64, filter (TC) 3, cell temperature 35°C. The injection volume was 10 
J.lL and the mobile phase was water vacuum degassed for fifteen minutes prior to use. 
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4.2.3 Testing Parameters 
Testing of the chromatographic method was performed in accordance with 
International Conference on Harmonisation (ICH) guidelines and typical operating 
procedures for pharmaceutical analysis. The test parameters are presented in the same 
order as they were investigated during the method validation. Specificity was determined 
by exposing ophthalmic solution samples, placebos, and standards of PEG400, glycerin 
to stress conditions of acid, base, hydrogen peroxide, light, and heat. Subsequently, the 
solutions were analyzed according to the method presented in this paper to ensure no 
extraneous peak co eluted with the actives. A refractive index detector was used during 
validation to ensure that no interfering compounds co-eluted with PEG400 and glycerin. 
Accuracy was measured by spiking ophthalmic solutions without PEG400 and glycerin 
with PEG400 and glycerin at three working levels of 70%, 100%, and 130% of the 
standard concentration. Actual concentrations tested for PEG400 I glycerin are: 0.399 
mg/mL I 0.089 mg/mL, 0.57 mg/mL I 0.13 mg/mL, 0.74 mg/mL / 0.169 mg/mL. Six 
preparations were performed at each level and assayed as per method conditions. The 
average result from each individual level was compared to its respective theoretical 
concentration value to check for any potential bias. 
To ensure that the method was linear in the working concentration range, five 
concentration level solutions of PEG400 and glycerin, corresponding to 0.287-0.862 
mg/mL for PEG400 and 0.064-0.192 mglmL for glycerin (about 50-150% of the expected 
analyte concentration) were prepared and injected. In addition, the ability of the system to 
retain and carryover the analyte into subsequent injections were evaluated by injecting a 
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blank solution (diluent only) in duplicate immediately after the 150% linearity level. To 
ensure performance of the system before and during the analysis, system performance 
parameters, as defined in USPINF, were established as a direct result of ruggedness and 
robustness experiments [147]. 
System precision was determined using six replicate measurements of a 100% 
theoretical concentration standard solution (0.57 mg/mL and 0.13 mg/mL for PEG400 
and glycerin concentration respectively) containing PEG400 and glycerin, with an 
acceptance criterion of the RSD being less than 2.0%. Repeatability was determined by 
six identical sample preparations of the same lot. To determine agreement among test 
results obtained from mUltiple samplings of the same lot of samples on different days 
using different instruments, columns and analysts, six identical samples from the same lot 
were prepared and analyzed. 
Robustness was determined by examining small variations in: flow rate (± 0.1 
mUmin) , column temperature (± 5°C). These parameters were changed one at a time. 
System suitability and sample runs were both conducted with unchanged method 
parameters and modified parameters. In addition a quantitative comparison study was 
performed between the raw material that was used to prepare the batch and other raw 
materials of PEG400 and glycerin including a USP reference standard. Three sample 
preparations were run and quantitated with four different standards as per the method. 
Further, to assess sample stability, standard and sample solutions were stored at room 
temperature and tested at initial, 24 hrs, 48 hrs, 72 hrs, 168 hrs and for some formulations 
up to 216 hrs. The solutions were tested against a freshly prepared standard at each time 
point. 
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4.3 Results and Discussion 
4.3.1 Developmental Work 
The physical and chemical properties of PEG400 and glycerin have been well 
established. The UV detector is possibly the most versatile and useful detector in high 
performance liquid chromatography, however it is not as widely used in SEC since many 
polymers do not absorb electromagnetic radiation in the UV range [35]. Utilization ofUV 
detection is possible if derivatization is being used. However, it would be difficult to 
derivitize both analytes at the same time and analyze them simultaneously, not to mention 
the added complexity of the sample preparation. For these reasons and the fact that both 
compounds do not absorb electromagnetic radiation in the UV range, differential 
refractive index detection was selected for this work. Refractive Index is a universal 
detector and is widely used in size exclusion chromatography (SEC) for compounds 
without significant chromophore [70]. Detection is achieved by monitoring changes in 
the refractive index of the mobile phase in the presence of PEG400 and glycerin 
molecules. Thus the combination of SEC with refractive index detection is especially 
suited to this application. 
The main goal during method development was to have an isocratic method that 
separates PEG400 and glycerin from other compounds in the formulation or degradation 
products. In this study that was not necessary since the molecular weight range of 
PEG400 and glycerin were well defined, approximately 400 g/mol (range 380-420 g/mol) 
for PEG400 and 92.09 gimol for glycerin and that information was furnished by the 
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vendor. Initially, several size exclusion columns from different manufacturers were 
screened and TSK-gel G2000PW. 7.5 mm ID x 30 cm x 12 ~m column was selected 
based on symmetrical peak shape of PEG400 and glycerin. TSK-gel columns in general 
consist of hydrophilic polymethacrylate spherical beads with sizes ranging from 12 ~m to 
17 ~m. These types of columns are suitable for the analysis of water soluble polymers 
and more specific the G2000PW is suitable for small (2000 Da and less) molecular 
weight polymers. As seen in Figure 16, in our method the TSK-gel G2000PW column is 
used in the expected context with smaller molecular weight analytes (glycerin) eluted 
later than analytes with higher molecular weight (PEG400). Other compounds present in 
the formulation, with molecular weights less than 2000, elute in the separation range of 
the column and if they are are smaller than glycerin will be eluted substantially later. If 
they are larger than PEG400 will be eluted earlier than the PEG400. In many of the 
sample chromatograms that were obtained, an additional peak was observed prior to 
PEG400 peak which we believe to be hydroxypropyl methylcellulose (HPMC): another 
polymer (higher in molecular weight than PEG400) used in ophthalmic solutions. Figure 
16 shows a chromatogram of this run with all three peaks (HPMC, PEG400, glycerin) 
separated. 
In general, polymers outside the upper limit of the exclusion volume range of the 
column will elute before the void volume. While uncommon, quantifying a peak eluting 
before the void volume has been recently reported in a similar context for the group assay 
of polyvinylsulfonic acid impurities in 2-(N-morpholino)-ethanesulfonic acid and 
polyvinylpyrrolidone [35, 71]. 
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Figure 16: Sample chromatogram with hydroxypropyl methy1cellulose (HPMC), PEG400 and 
glycerin 
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Figure 17 clearly shows a very symmetrical peak for PEG400 and glycerin, 
demonstrating a satisfactory tailing factor for system performance. The validation data 
presented below demonstrate adequate precision. 
In an ideal SEC method separation is based on molecular size of the analyte 
relative to the pore size of the packing material without any interactions between the 
analyte and the packing materiaL However, a small number of weakly charged groups at 
the surface of the packing material can cause changes in elution order or peak distortion. 
Mobile phase selection is important to avoid enthalpic interactions between the analyte 
and the packing material. There are a variety of solvents compatible with TSK-GEL 
columns, so the selection process depends on the chemical structure, ionic nature and 
solubility of the analytes [72]. In this study, water was used as the ideal mobile phase 
because both PEG400 and glycerin are soluble in water. A good peak shape was observed, 
with the expected elution order, which is a clear indication that there are no interactions 
between the packing material and the analytes. To avoid microbial growth in the column 
which can cause erroneous peaks and peak distortion in future analyses the column rinsed 
with 0.5% sodium azide prior to storage [124]. 
Temperature adjustment can reduce the analysis time and improve 
chromatographic performance. More specifically, as the· temperature increases, the 
viscosity of the mobile phase decreases and the diffusivity of the analyte increases. Fast 
size exclusion chromatography has been discussed in the literature and temperature is one 
of the primary parameters adjusted to achieve faster analysis times [73-74]. Optimum 
chromatographic performance was obtained in this method with column temperature at 
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Figure 17: Chromatogram of PEG400 and glycerin standard (a): Full scale chromatogram (b): Expanded 
chromatogram 
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4.3.2 Experimental Work 
Figure 18 shows the analysis of PEG400 and glycerin in several different 
formulations that contain both PEG400 and glycerin (top), only glycerin (middle) and 
only PEG400 (bottom). PEG400 and glycerin do not appear in the placebo 
chromatograms because it is simply a formulation prepared without the analytes used to 
demonstrate that other compounds that commonly appear in ophthalmic formulations will 
not interfere with the method. Figure 19 shows overlay standard chromatograms with 
ophthalmic solutions that doesn't contain PEG400 and glycerin, glycerin (top) and 
PEG400 (bottom). These chromatograms clearly demonstrate that SEC can be used for 
the separation of PEG400 and glycerin from other formulation components. 
Chromatographic performance of the system was evaluated for each run by measuring the 
precision of six injections of PEG400 I glycerin working standard, tailing factor, 
resolution between analytes or any excipient that elutes close to method analytes. 
The specificity of the method was tested by stressing standards of PEG400 I 
glycerin and ophthalmic solutions with and without PEG400 I glycerin. No interference 
was observed for the PEG400 and glycerin peaks from the forced degradation samples 
and standards. During these studies equivalent amounts as per method of ophthalmic 
solution samples, ophthalmic solution without PEG400, glycerin, and PEG400, glycerin 
standard were stressed for the following conditions: (1) heat at 75°C for 1 hr; (2) 5 mL of 
1 N hydrochloric acid at 75°C for 1 hr; (3) 5 rnL of 1 N sodium hydroxide at 75°C for 1 
hr; (4) 5 rnL of 30% hydrogen peroxide at 75°C for 1 hr; and (5) light exposure for 24 hrs 
as per ICH option 1. 
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Figure 18: Different sample chromatograms (a) contain both PEG400 and Glycerin. (b) only 
glycerin, (C) only PEG400 
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Samples during this option were exposed to light providing an overall illumination of not 
less than 1.2 million lux hours and an integrated near ultraviolet energy of not less than 
200 watt hours/square meter. Subsequently the solutions were cooled to room 
temperature, neutralized (if needed) and analyzed according to the test procedure. To 
ensure that the method is stability indicating and no extraneous peaks co-eluted with the 
peaks of interest, the stress samples of ophthalmic solutions and standards were run for 
60 minutes. No interference was observed during stressing of these samples. A peak that 
was observed at an approximate retention time of 12 minutes during stressing (with 
hydrogen peroxide in all of the samples) is attributed to peroxide solution and is not 
related to degradation of PEG400 and glycerin. Figure 20 shows overlay chromatograms 
of ophthalmic solutions without glycerin (a) without PEG400 (b) and complete 
ophthalmic solution sample (c) at different stress conditions. 
Linearity of the method was established by injecting five standard concentrations 
of PEG400, glycerin and preparing a calibration curve by plotting PEG400, glycerin 
response versus concentration. The solutions covered a concentration range of 0.287 ­
0.8622 mglmL for PEG400 and 0.0642 - 0.1925 mglmL for glycerin. The linearity curve 
for PEG400 and glycerin are presented in Figures 21 and 22. The solutions covered a 
range of 50%-150 % of theoretical concentration 0.128 mglmL and 0.5748 mg/mL of 
glycerin and PEG400 respectively. The method was linear in this range with R2 values of 
0.9999. Concentration of linearity solutions, responses and linearity parameters such as 
slope, y-intercept, and coefficient of determination are listed on Tables 10 and 11. No 
carryover was observed into blank injections immediately after the highest level linearity 
standard, ensuring independence of the samples. 
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Figure 20: Overlay chromatograms of ophthalmic solutions without glycerin (a) without PEG400 (b) and 
complete ophthalmic solution sample (c) at different stress conditions 
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Figure 21: Linearity graph of PEG400 
81 

Target Concentration ResponseConcentration (mglmL) (Peak Height) Level 
50% 0.2874 6707.58 
80% 0.4311 10017.79 
100% 0.5748 13326.56 
130% 0.7185 16683.16 
150% 0.8622 20012.49 
Slope 23156.01 
Y Intercept (%) 39.44 
Correlation 0.999993 
Table 10: PEG400 linearity parameters 
82 

12000 
~ 10000 
c 
o 
~ 8000 
~ 
.! 6000 
.!!P 
11/
::c 
~ 
i 
4000 
2000 
0.000 0.050 0.100 0.150 0.200 0.250 
Linearity of Glycerin 
y= 54,09L566641x-36.408000 
R2 =0.999972 
• Seriesl 
• Series2 
--Linear (Series2) 
Concentration mg/ml 
-------.~------------~--~--..~--------' 
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Target 
Concentration 
Level 
Concentration 
(mglmL) 
Response 
(Peak Height) 
50% 0.064150 3442.01 
80% 0.096225 5173.94 
100% 0.128300 6878.86 
130% 0.160375 8637.95 
150% 0.192450 10384.94 
Slope 54091.567 
Y Intercept (% ) -36.408 
Correlation 0.999972 
Table 11: Glycerin linearity parameters 
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System precision was established by six replicate measurements of a 100% 
theoretical standard solution of PEG400 and glycerin. The %RSD for PEG400 and 
glycerin was found to be 0.1% and 0.4% respectively. Table 12a shows the system 
precision results, mean and standard deviation. 
Repeatability was evaluated by six identical sample preparations of a 
homogeneous batch and the results were found to be within the specifications. The 
percent relative standard deviation of the six preparations for PEG400 and glycerin was 
found to be 0.5% and 0.2% respectively. In order to further validate the results, the 
experiment was conducted again on a different day using a different instrument, column 
and analyst. In addition the work was repeated at a different work site, using different 
instruments and different columns. The experimental mean agreement for PEG400 
between the two days and sites was found to be 1.6% and 0.4% respectively. This is 
within the acceptance criteria. Results are displayed in Table 12b. The experimental 
mean agreement for glycerin between the two days and sites was found to be 1.2% and 
0.2% respectively; also within the acceptance criteria. Results are displayed in Table 12c. 
The accuracy of the method was established by assaying three different 
concentration levels 70%, 100%, and 130% of the theoretical concentration. Six 
preparations of ophthalmic solutions without PEG400 and glycerin, were spiked at each 
level with standard of PEG400 and glycerin and were injected into the HPLC system. 
Results are reported in Table 13a with PEG400 mean recovery values varying from 
99.7% to 100.0 % of the prepared standard concentration. No bias was observed for 
PEG400, because the results for the mean recovery 
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Peak Response (PEG400) Peak Response (Glvcerin)I Replicate # 
Peak Hei~ht 
5840.56 
i 
1 14567.82 
I2 14520.11 5872.62 
3 14510.00 5869.59 
4 I 14528.96 5892.72 
5 I 14540.22 5910.14 
6 I 
: 
14517.93 5890.99 I 
Mean I 14530.84 5879.44 
%RSD 0.1 0.4 
i 
i 
I 
I 
(a) 
I 
i Replicate 
I % Label Claim of PEG400 (%LC) 
Intermediate Precision Reproducibility 
Analyst 1ILab 1 Analyst 2ILab 1 Lab 1 Lab 2 
101.01 • 100.9 100.2 100.9 
2 101.7 99.8 101.7 101.7 I 
3 102.0 100.6 102.0 101.5 
4 102.6 99.9 102.6 101.4 I 
5 101.5 99.9 101.5 101.5 I I 
6 101.4 100.1 101.4 101.0 
Mean .101.7 100.1 101.7 101.3 
i %RSD 0.5 0.3 0.5 0.3 
Mean Agreement 1.6% 0.4% 
I 
I 
% Label ClaiQ'l of Glycerin (%LC) I 
Replicate Intermediate Precision Reproducibility 
Anal st llLab 1 Analyst 2ILab 1 Lab 1 Lab 2 
I 199.2 101.0 99.2 99.2 
2 99.9 100.3 99.9 99.7 
3 I 99.3 101.7 99.3 100.0 
4 99.7 101.0 99.7 99.5 
5 • 99.6 100.7 99.6 99.3 
6 99.4 99.6 99.4 98.6 i 
Mean . 99.5 100.7 99.5 99.4 I 
%RSD 0.2 0.7 0.2 0.5 
Mean Agreement 1.2% 0.2% 
I 
(c) 
Table 12: Experimental resu s (a) system precision results for PEG400 and glycerin, (b) Intermediate 
method precision and reprod ~cibility results for PEG400, (c) Intermediate method precision and 
reproducibility results for gh cerin 
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(b) 
I 
Prep # PEG400 
Mean Recovery Value %LC 
70% Level 100% Level 130% Level· 
1 99.9 99.7 99.8 
2 99.6 100.0 99.7 l 
3 100.0 100.1 100.4 
4 100.0 99.9 98.7 I 
5 99.0 100.3 100.0 
6 99.6 100.0 100.0 
Mean 99.7 100.0 99.8 
%RSD 0.4 0.2 0.6 
(a) 
Prep # Glycerin 
Mean Recovery Value %LC I 
70% Level 100% Level 130% Level 
1 I99.6 99.699.2 
2 100.2 99.9 99.7 
3 100.3 100.0 100.0 
4 99.799.5 100.2 
5 100.0 100.0 100.1 
6 99.0 100.3 
Mean 
99.9 
99.9 
%RSD 
99.8 99.9 
0.30.5 0.4 
(b) 
Table 13: Experimental accuracy results of (a) ophthalmic solution without PEG400 spiked with PEG400 
standard at three levels, 70, 100, 130% of theoretical (b) ophthalmic solution without glycerin spiked with 
glycerin standard at three levels, 70, 100, 130% of theoretical. 
87 

from all three accuracy levels were not significantly lower or higher (±l.S%) than the 
theoretical value. Results are reported in Table 13b with glycerin mean recovery values 
varied from 99.8% to 99.9% of the prepared standard concentration. No bias was 
observed for glycerin, because the results for the mean recovery from all three accuracy 
levels were not significantly lower or higher (±1.5%) than the theoretical value. The 
range in which the method is shown to be linear and accurate for PEG400 and glycerin is 
between 70-130% of theoretical concentration. 
The method was unaffected by small, deliberate variations in chromatographic 
parameters and mobile phase preparation. The parameters tested were mobile phase flow 
rate (+1- 0.1 mUmin) and temperature (+1- 4°C). The peak shape of PEG400 and glycerin 
were not affected by these parameters but in general higher variability results were 
observed for the PEG400 robustness study. The variation in results that was observed 
between the normal method conditions and the changed parameters were from 0.2 to 
2.3% for PEG400 and 0.1 to 0.3% for glycerin. Table 14a and 14b show the results that 
were obtained by the robustness studies of PEG400 and glycerin respectively. 
Two different lots of glycerin raw materials were used to evaluate the impact to 
the assay values using glycerin other than the one used in the formulation batch. In 
addition, USP reference glycerin standard and Sigma Aldrich glycerin were evaluated to 
quantitate glycerin in ophthalmic solutions. Three sample preparations were run with four 
different glycerin standards as per method. Table 15a summarizes the results of this study. 
In attempt to explain the variability on the results the water content of each standard of 
glycerin was investigated by assaying water content via Karl Fischer as per United States 
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Parameters under study 
Control 
Flow 0.9mVrnin 
% LC of PEG400 
98.8 
lOLl 
Percent difference 
N/A 
2.3 
Flow l.lml/min 
Control 
Column temperature 46° C 
99.1 
101.5 
101.3 
0.3 
N/A 
0.2 
I 
Column temperature 54° C 101.2 0.3 
(a) 
Parameters under study % LC of glycerin Percent difference 
Control 97.7 N/A 
Flow 0.9mVrnin 97.4 0.3 
Flow 1.1 ml/rnin 97.4 0.3 
Control 98.5 N/A 
Column temperature 46° C 98.8 0.3 
I Column temperature 54°C 98.4 0.1 
(b) 
Table 14: Results of robustness studies for (a) PEG400 and (b) glycerin 
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I 
Standard 1 Standard 2 Standard 3 Standard 4 
Raw Material Raw Material Sigma Aldricll USP 
% Label Claim of glycerin 
Assay prep-I 101.6 97.0 97.2 97.6 
Assay prep-2 101.8 97.5 97.2 97.5 
Assay prep-3 101,5 96.8 96.4 96.9 
Mean 101.7 97.1 96.9 97.4 
Absolute difference from 
N/A 4.6 4.8 4.3 
Standard 1 
(a) 
I Standard 1 Raw Material Standard 2 Standard 3 Raw Material Sigma Aldrich 
% water content 
Standard 4 
USP 
Water content 4.31 0.06 0.13 1.03 
Absolute difference from 
Standard 1 
N/A -4.25 -4.18 -3.28 
(b) 
Standard 1 
Raw Material 
Standard 2 
Raw Material 
Standard 3 Standard 4 
Sigma Aldrich USP 
% Label Claim of glycerin 
Assay prep-l 101.6 101.3 101.4 100.9 
I 
Assay prep-2 101.8 101.8 101.4 100.8 
Assay prep-3 101,5 101.1 100.6 100.2 
Mean 101.7 101.4 101.2 100.6 
Absolute difference from 
Standard 1 
N/A 0.3 0.5 1.1 
I 
I 
(c) 
Table 15: Experimental results of (a) assay ophthalmic formulation using different sources of glycerin as a 
standard (b) Water content of glycerin standards (c) Assay of ophthalmic formulations corrected for water 
content 
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Phannacopeia 30 <921> method 1. Table 15b summarizes the water content results of 
glycerin. The water results explain the variability that was observed for the assay values 
when different standards were used. Correcting the assay values for water content brings 
the assay results within agreement to each other. Table 15c has the glycerin results 
corrected for water content. Standard glycerin will be evaluated for water content prior of 
using it for the analysis of ophthalmic solutions. 
Two different lots of PEG400 raw materials were used to evaluate the impact on 
the assay values of using different materials of PEG400. In addition, USP reference 
PEG400 standard was evaluated by quantitate PEG400 in ophthalmic solutions. Three 
sample preparations were run with three different PEG400 standards as per method. 
Table 16a summarizes the results of this study. Even though the results were within 
experimental error from each other, additional verifications were performed. For example, 
water content of each standard of PEG400 was determined by Karl Fischer as per USP 30 
<921> method I, to asure that there is no bias to assay results. Table 16b summarizes the 
water content results of PEG400. A small amount of water was found by Karl Fischer 
titration but assay results should not change much if they corrected. Water determination 
for PEG400 standards prior to sample analysis was not necessary. Correction of assay 
values for water content did not change the results drastically and results are within the 
method variability and agreement to each other. Table 16c has the PEG400 results 
corrected for water content. 
The stability of the standard and sample solutions for PEG400 and glycerin was 
also evaluated. No significant change in PEG400 and glycerin response was observed 
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Standard 1 
Raw Material 
Standard 2 
Raw Material 
Standard 3 
USP 
% Label Claim of PEG 400 
Assay prep-l 100.3 99.2 100.3 
Assay prep-2 99.9 98.7 100.7 
Assay prep-3 99.6 99.4 100.9 
Mean 
Absolute difference from 
Standard 1 
99.9 
N/A 
99.1 
0.8 
100.7 
0.8 
(a) 
Standard 1 Standard 2 Standard 3 
Raw Material Raw Material USP 
i 
Water content 0.82 
% water content 
0.09 0.44 
Absolute difference from 
Standard 1 
N/A -0.73 -0.38 
(b) 
I 

I 
I 
(c) 
Table 16: Experimental results of (a) assay ophthalmic formulation using different sources of PEG400 as a 
standard (b) Water content of PEG400 standards (c) Assay of ophthalmic formulations corrected for water 
content 
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Standard 1 Standard 2 
Raw Material Raw Material 
Standard 3 
USP 
% Label Claim of glycerin 
Assay prep-l 100.3 99.9 100.7 
Assay prep-2 99.9 99.4 101.1 
Assay prep-3 99.6 100.1 101.3 
Mean 99.9 99.8 101.0 
Absolute difference from 
Standard 1 
N/A 0.1 1.1 
over a period of 192 hours. Solutions were stored at refrigerator and ambient temperature. 
Samples tested at the same time against freshly prepared standards of PEG400 and 
glycerin and results between the two conditions were comparable. Reference tables 17 
and 18 for the solution stability of both standard and sample respectively at ambient 
temperature. 
4.4 Conclusion 
A new method for the simultaneous determination of total PEG400 and glycerin in 
ophthalmic solutions was developed using SEC with refractive index detector. This fast, 
simple isocratic method separates PEG400 and glycerin from other excipients in the 
formulation. Validation for this method was performed according to ICR guidelines and 
met all acceptance criteria. The method is precise (+1- 0.5%), accurate (+1- 1%), and 
linear at concentration ranges of 0.064 mg/mL to 0.192 mg/mL for glycerin and 0.287 
mglml to 0.862 mglmL for PEG400, typical of prepared ophthalmic solution samples for 
glycerin and PEG400. This method provides a model for the simultaneous analysis of 
polymeric components such as PEG400 in the presence of other components such as 
glycerin in a number of different types of formulations. 
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PEG400 Glycerin 
Time Point 
Initial 
Response 
(%LC) 
99.7 
% Difference 
from Initial 
N/A 
Response 
(%LC) 
99.9 
% Difference 
from Initial 
N/A 
i 
24 Hours 100.2 -0.5 100.1 -0.2 
48 Hours 100.5 -0.8 100.2 -0.3 
I 
72 Hours 100.7 -1.0 99.9 0.0 
f 168 Days 101.1 -1.4 100.3 -0.4 
(a) 
PEG400 Glycerin 
Time Point Response 
(%LC) 
% Difference 
from Initial 
Response 
(%LC) 
% Difference 
from Initial 
Initial 99.7 N/A 99.9 N/A 
24 Hours 100.4 -0.7 101.1 -1.2 
48 Hours 100.8 -1.1 99.9 0.0 
72 Hours 100.4 -0.7 100.6 -0.7 
168 Days 101.4 -1.7 101.0 -1.1 
(b) 
Table 17: Standard solution stability studies at (a) ambient temperature (b) refrigerated 
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I 
I 
PEG400 Glycerin 
Time Point Response % Difference Response % Difference 
from Initial from Initial (%LC) (%LC) 
Initial N/A101.8 N/A104.0 
24 Hours 102.7 0.9 104.7 0.7 
48 Hours 102.4 0.6 104.6 0.6 
72 Hours 102.3 0.5 104.2 0.2 
196 Days 102.3 104.50.5 0.5 
(a) 
I 
I 
PEG400 Glycerin 
Time Point Response 
(%LC) 
% Difference 
from Initial 
Response 
(%LC) 
% Difference 
from Initial 
Initial 101.8 N/A 104.0 N/A 
24 Hours 103.0 1.2 104.6 0.6 
48 Hours 102.6 0.8 104.6 0.6 I 
72 Hours 102.6 0.8 104.2 0.2 
8 Days 102.2 0.4 104.5 0.5 
I 
I 
I 
(b) 
Table 18: Sample solution stability studies at (a) ambient temperature (b) refrigerated 
95 
Chapter 5: Ophthalmic Active Components 
5.1 Introduction 
In pharmaceutical work active components are defined by the International 
Committee on Harmonization (ICH Q7A) as "any substance or mixture of substances 
intended to be used in the manufacture of a drug product and that, when used in the 
production of a drug, becomes an active ingredient in the drug product". Such substances 
are intended to furnish pharmacological activity or other direct effect in the diagnosis, 
cure, mitigation, treatment or prevention of disease or to affect the structure and function 
of the body. Any ophthalmic solution is composed of two aspects. The first is the active 
component which is the central ingredient or the therapeutic agent that is meant to 
produce the desired effect in the body. The second is the rest of the components in the 
formulation that are used to deliver the active components or play a role in solution 
stability but that do not have a direct therapeutic purpose in the ophthalmic solution. 
There is a variety of over the counter ophthalmic solutions that can be applied or 
instilled in the eye for the treatment of symptoms such as itching, irritation, redness, 
dryness, tearing, conjunctival edema, burning and discharge. There are different active 
components for the symptoms above and in some instances they might be multiple 
actives for the treatment of several symptoms at once. 
General categories of active components in ophthalmic solutions are 
vasoconstrictor, hypertonicity agent, emollient, astringent, and buffering agent [148]. A 
vasoconstrictor is a topically pharmacologic agent that when applied to the mucous 
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membranes of the eye causes constriction of conjunctival blood vessels. There are five 
active components in this category that can be found in ophthalmic solutions: 
oxymetazoline hydrochloride, naphazoline hydrochloride, tetrahydrozoline 
hydrochloride, ephedrine hydrochloride, and phenylephrine hydrochloride. Hypertonicity 
agents exert an osmotic pressure greater than that present in body tissues and fluids, so 
that water is drawn out from the body tissues and fluids across semipermeable 
membranes. Applied topically in the eye, they create an osmotic pressure which draws 
water out of the cornea. Sodium chloride at levels of 2% to 5% is one of the most 
common hypertonic agents. Emollients are usually fat or oil, which applied locally to 
eyelids protect and soften tissues to prevent drying and cracking. Examples of the most 
used emollients in ophthalmic formulations are lanolin, mineral oil, petrolatum, and 
paraffin. An astringent is a therapeutic local agent which precipitates protein and helps to 
clear mucous from the outer surface of the eye. Zinc sulfate is an example of an 
astringent in ophthalmic solutions and can be found at 0.25% concentration. A buffering 
agent stabilizes pH when acid or base is introduced to the eye in the form of body fluids 
and tears. 
Analysis of the active component, along with possible degradants and impurities 
is critical to ophthalmic solutions due to the efficacy of the ~ctive component and due to 
regulatory requirements. Recently not only the purity profile but the impurity profile has 
become essential for the safety of the ophthalmic formulations because small amounts of 
unwanted impurities can influence the safety and efficacy. Different pharmacopoeias 
such as United States Pharmacopoeia, and British Pharmacopoeia, which regulate 
ophthalmic solutions, are incorporating limits for acceptable levels of known impurities 
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of active components. 
In this chapter, oxymetazoline hydrochloride was chosen to be studied extensively 
and additional active components which have similar structures (tetrahydrozoline 
hydrochloride and naphazoline hydrochloride) were also evaluated to establish common 
degradation pathways through stresS degradation studies. 
One challenge in the analysis of ophthalmic solutions is the measurement of 
oxymetazoline hydrochloride (OXY) and its known degradation product (N-(2­
aminoethyl)-2-[4-(I,ldimethylethyl)-3-hydroxy-2,6-dimethylphenyl]-acetamide) (OXY­
, DEG). Although a number of HPLC methods have been developed to determine OXY in 
a variety of products, [149-153] none of these methods also determined OXY-DEG, 
which appears at much lower concentration. In this work, a straightforward, isocratic 
reversed-phase HPLC-UV method was sufficient to quantify both OXY and OXY -DEG 
in a single analysis, although their concentrations are orders of magnitude different. 
Forced degradation studies performed during method validation revealed that OXY -DEG 
is likely a base hydrolysis product of OXY. In ~ddition, other ophthalmic active 
components with the same imidazoline structure were stressed and tested to verify 
degradation pathway similar to the unknown of OXY. Figure 23 shows the structures of 
tetrahydrozoline and naphazoline that were used during stress studies to confirm the 
degradation pathway. 
A simple rapid isocratic reversed-phase high performance liquid chromatography 
(HPLC) method was developed for the determination of oxymetazoline hydrochloride 
(OXY) and its known degradation product (N-(2-arninoethyl)-2-[4-(1,1-dimethylethyl)-3­
hydroxy-2,6-dimethylphenyl]-acetamide) in ophthalmic solutions. 
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(a) 
Tetrahydrozoline 
Structural name: 
2-Tetralin-l-yl-4,5-dihydro-lH-imidazole 
Molecular formulation: CI3Hl~2 
Formula wei!!ht: 200.28 
H:) 
N 
(b) 
Naphazoline 
Structural name: 2-(naphthalen-l­
ylmethyl)-4,5-dihydro-lH-imidazole 
Molecular formulation: C'4H'4N2 
Formula weight: 210.274 
Figure 23: Imidazoline structures (a) Tetrahydrozoline (b) Naphazoline 
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Oxymetazoline hydrochloride (OXY) is a long acting vaso-constrictor that acts 
directly to reduce the swelling of the nasal membranes, relieving decongestion in the 
subject. In the eye, imidazole decongestants such as OXY are used to constrict 
conjunctival blood vessels. More specific ophthalmic solutions that contain OXY have 
been shown to improve the relief of redness in the eye due to minor eye irritations [147]. 
OXY is an imidazole derivative with a general formula: [CI6H24N20]· HCI, and chemical 
name3-[( 4,5-dihydro-1H-imidazol-2-yl)methyl]-6-( 1, 1-dimethylethyl)-2,4­
dimethylphenol hydrochloride. The chemical structure of oxymetazoline hydrochloride is 
presented in Figure 24. 
OXY is an ingredient in a variety of over-the-counter products such as nasal 
sprays and ophthalmic solutions. It was developed at E. Merck Darmstadt, Germany from 
xylometazoline in 1961 [154]. OXY has sympathomimetic properties meaning it 
constricts the blood vessels of the nose and sinuses through the activation of alpha 
adrenergic receptors. However, the treatment should not be continued for more than 
seventy two hours since excessive or improper use of topical decongestants can cause 
rhinitis medicamentosa which is increased nasal congestion [155]. Recently, it has been 
reported that OXY inhibits and resolves inflammatory reactions in human neutrophils 
[156]; a type of white blood cell filled with neutrally-staining granules, tiny sacs of 
enzymes that help the cell to kill and digest microorganisms. 
Ophthalmic solutions and nasal sprays generally contain OXY at levels of 0.025% 
to 0.05% respectively [147, 157]. Many high performance liquid chromatography 
analytical methods have been developed to determine OXY in a variety of products [149­
153, 158-159]. 
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Figure 24: Oxymetazoline structure 
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However, none of these methods also determined the known degradation product of 
Oxymetazoline: N - (2 - aminoethyl) - 2 - [4 - (1,1 - dimethylethyl) - 3 - hydroxyl - 2,6 ­
dimethylphenyl] - acetamide (OXY-DEG). 
The European Pharmacopeia (EP) lists OXY -DEG as a known impurity of 
oxymetazoline hydrochloride with chemical name N-(2-aminoethyl)-2-[4-(l,I­
dimethylethyl)-3-hydroxy-2,6-dimethylphenyl]-acetamide [160]. The chemical structure 
of the impurity is shown in Figure 25. However, during the stress studies of the method 
validation, it was determined that this compound is a hydrolysis product of 
oxymetazoline hydrochloride which is consistent with information published in literature 
[161]. 
The method of determination of the OXY-DEG as described in EP is different than the 
one in this publication. More specific the differences are in the column dimensions, stationary 
phase, column temperature, flow, wavelength, and mobile phase. The USP method is only 
suitable for the assay determination of OXY and doesn't determine the OXY -DEG. In addition, in 
that USP assay method the chromatographic parameters are different than the current method. 
The EP assay method the determination of OXY was done with titration and not with an HPLC 
[160, 162]. 
In this work we describe new HPLC methods for the analysis of the 
oxymetazoline hydrochloride and its degradation product in ophthalmic solutions. The 
new methods are stability indicating methods and were successfully validated based on 
the International Conference on Harmonization guidelines [163]. 
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j NHZ xHel 
N 
H 
Figure 25: Structure of oxymetazoline degradation product (N (2 aminoethyl) - 2 - [4 - (1,1 ­
dimethylethyl) - 3 - hydroxyl- 2,6 - dimethylphenyl] - acetamide) 
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5.2 Experimental 
5.2.1 Reagents and Chemicals 
Standards of oxymetazoline HCl and its degradation product were obtained from 
LGC (LGC GmbH, 1m Biotechnologiepark, TGZ II, D 14943 Luckenwalde, Germany). 
Samples and placebo were provided by the Johnson and Johnson product development 
group (Morris Plains, NJ, USA). ACS reagent grade sodium acetate trihydrate and 
reagent grade glacial acetic acid were purchased from Sigma Aldrich (Saint Louis, 
Missouri, USA). HPLC grade acetonitrile was purchased from J.T. Baker (Phillipsburg, 
NJ, USA). Deionized Water was used and obtained from VWR International, LLC (West 
Chester, Pennsylvania, USA). 
5.2.2 Equipment 
An Alliance HPLC system (Waters Corporation, Milford, Massachusetts, USA) 
was used for method development and validation. The Alliance LC system was equipped 
with 2695 separation module, 2487 UV detector and 996 photodiode array detector. Data 
collection and processing was done using Empower (Waters Corporation, Milford, MA 
USA). 
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5.2.6.9.2 Solution Stability: Standard and sample solutions were stored at room 
temperature and tested at initial, 72 hrs and 240 hrs of standing. The solutions were tested 
against a freshly prepared standard at each time point. 
5.3 Results and Discussion 
The analytical method for the degradation product of oxymetazoline hydrochloride is 
slightly different than the assay method of OXY since the exact parameters were not 
suitable to evaluate both compounds simultaneously in one method. More specifically, 
the differences were in detector wavelength and injection volume. These are not unusual 
since the target concentration level and UV absorbance between the OXY and 
degradation product can be different. However, the determination of OXY and 
degradants can be done in a single injection with the use of dual wavelength or 
photodiode array UV detectors. Additional validation of the method was done at 100 ",,1 
injection volume. More specific the following parameters were evaluated: system 
precision, method precision, accuracy and linearity. The degradation method is also 
capable of separating xylometazoline hydrochloride from OXY and OXY -DEG. 
However, xylometazoline was not included into validation since it was not observed 
during the stressing studies at specificity. Figure 26 shows an overlay chromatogram of 
ophthalmic solution sample with mixture standard OXY -DEG and xylometazoline 
hydrochloride. 
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Figure 26: Overlay chromatogram of ophthalmic solution sample and degradation standard mixture 
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I 
I 
1 
t 
! 
J 5.3.1 Developmental Work 
I The physical and chemical properties of oxymetazoline hydrochloride are well established, since that molecule has been known since its synthesis in 1961 [149]. UV 
I 
I detection was selected since both oxymetazoline HCI and its degradation product have a 
I 
J 
chromophore at UV spectrum range. Figure 27 shows UV spectra of (a) oxymetazoline 
I and (b) OXY-DEG. 
,I 
The initial goal during the method development was to have one method for the i 
I 
j 
determination of oxymetazoline and its degradation product. However, it was observed 
that oxymetazoline response was not linear at wavelength of 225 nm and injection 
volume of 100 !AL. Optimum wavelength selection (A=225 nm) for the degradation 
1 
method was done based on the maximum absorbance of degradation product. The 
wavelength (A=280 nm) of the assay method was selected based on the second maximum 
absorbance of the oxymetazoline. Nevertheless, the determination of OXY and its 
degradation product can be done in a single chromatographic run with the use of 
photodiode array detector. 
Ideally in reversed phase HPLC method development, several columns with 
different stationary phases Cg, CIg, Cyano, Phenyl, should be tested based on separation 
ability in the desired pH range. However, in cases that there is familiarity with the active 
ingredient the use of a single column can be sufficient for method development. In this 
case, the cyano stationary phase (Agilent, Zorbax SB-CN, 3.5 !Am, 150 mm x 4.6 mm) 
proved capable of adequately separating all components, so testing of other columns was 
not necessary. 
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Figure 27; UV spectrum of (a): OXY (b): OXY -DEG 
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In general, retention of less polar compounds declines with cyano columns while polar 
compounds maintain retention. Many comparable studies were reported between cyano 
and different stationary phases. In one such study, different cyano columns were 
characterized in terms of selectivity. Comparison between cyano, C8, and C18 stationary 
phases was not practical because cyano columns required weaker mobile phases with 
changes in separation selectivity. Due to those differences replacement of C8, and CI8 
columns with an equivalent cyano column will not be possible [166]. 
System performance. parameters were selected to provide confidence that the 
methods are capable of determining oxymetazoline HCI and OXY -DEG in ophthalmic 
solutions. Different concentration levels of oxymetazoline HCI were injected as part of 
the system suitability for the two methods. Typical chromatograms for oxymetazoline 
HCI standard solution are shown in Figure 28. The selected system performance 
parameters were injection precision of OXY, tailing factor and signal to noise ratio of 
OXY at the quantitation level. In addition, check standard conformity and bracketing 
standard conformity were proved during each chromatographic run. All of these tests 
produced results within the guidelines of good laboratory practices for system 
performance. The system performance at 100 ""L injection volume was based on the 
precision of six injections of a 100% standard at concentration 0.1 mglmL. Tailing factor 
and signal to noise ratio were not evaluated as part of the system suitability. The tailing 
factor that was observed during the validation at this injection volume was greater than 
the previous acceptance criteria of 0.8-2.0. This is not unusual since the amount of OXY 
in the column is ten times higher than the 10 ""L injection. Also, during this injection 
adequate signal to noise ratio was observed which make this parameter unessential to 
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Figure 28: Chromatograms of oxymetazoline for (a): Assay method (b): Degradation method 
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monitor as part of the system suitability. Typical chromatogram for the oxymetazoline 
Hel standard is shown in Figure 29. In addition, check standard and bracketing standard 
conformity were proved during validation. Samples bracketed with two different 
standards to accommodate the simultaneous determination of OXY and unknown 
degradants in the sample. The standard concentrations were 0.1 mg/mL and 0.001 mglmL 
for assay and degradation respectively. System suitability tests produced results within 
the guidelines of our standard operating procedures. 
5.3.2 Experimental Work 
The specificity of the methods (assay and degradation) was tested and no 
interference from inpurities or degradants was observed for the oxymetazoline 
hydrochloride and its degradation product peaks from placebo and forced degradation 
samples using acid, base, light, hydrogen peroxide and heating. To ensure no extraneous 
peak co-eluted with the OXY or its degradation product, a UV diode array detector was 
used to check peak purity using the full UV spectrum at several points on each peak [167]. 
Figure 30 shows overlay chromatograms at 225 nm of OXY standard stressed with acid, 
base, heat, light and peroxide showing no interference between OXY, OXY -DEG, 
excipients and impurities. It should be noted that during the oxidation stressing a peak 
that was observed around retention time of 1.1 minutes is due to the hydrogen peroxide 
solution and not oxymetazoline degradant. 
118 

0,28 
0,2& ~ 014 	 i0,22­
0,2(; 
OJ6 I \ 
I 
0.16 
'i 0.1' \ 
0.12 
0.10 \ 
0.08 \ 
0.08 
0.04 \ 
\ 
O.~ 
'is 
I ~~..00(; . 
0.50 	 1.00 1.50 2.00 2.50 3.00 3.&0 4.00 4.&0 5.00 5.50 6,00 850 7.00 
Mtl.... 
Figure 29: Typical chromatogram for oxymetazoline Hel standard of 100 /!L injection volume 
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Figure 30: Overlay chromatogram of OXY standard. From the bottom: Control. Acid, Base, Heat, Light 
and Oxidation 
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OXY-DEG was observed during the stressing conditions of the oxymetazoline standard 
with base. The standard was subjected to 0.1 N of sodium hydroxide at 75°C for one hour. 
The solution was cooled to room temperature, neutralized with equivalent amount of 0.1 
N hydrochloric acid and analyzed chromatographically. Hydroxide anion in the solution 
attack and attach to the carbon at the double bond of the imidazole ring. Furthermore the 
attached hydroxyl group converted into a ketone and causes the imidazole ring to open. 
That compound is the hydrolysis product of oxymetazoline hydrochloride. Figure 31 
shows the base hydrolysis reaction ofoxymetazoline. 
Linearity of the method was established. Five standard concentrations of 
oxymetazoline hydrochloride and OXY-DEG were prepared and injected. Oxymetazoline 
was injected at different concentration levels for each method of assay and degradation. A 
linearity graph was prepared by plotting the concentration versus the response of the 
actives. The solutions for the oxymetazoline assay method covered a range of 50-150 % 
of the hypothetical formulation concentration with corresponding concentration range of 
0.05 to 0.15 mg/mL. Table 19 and Figure 32 show the linearity parameters and the 
linearity graph for oxymetazoline assay method at wavelength 280 nm respectively. 
For the degradation method the OXY solutions cover a range of 70-130% of the 
theoretical formulation concentration and 0.1-3.0% range for OXY-DEG relative to 
oxymetazoline concentration. The range of the OXY -DEG was determined based on the 
ICH guidelines on impurities in new drug substances and new drug products (168-169]. 
The corresponding concentration range is 0.0007 to 0.0013 mg/mL and 0.0001 to 0.003 
mg/mL for the· OXY and. OXY -DEG respectively. The methods were linear in these 
ranges with R2 values of 0.999 in both OXY'and OXY-DEG. 
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Figure 31: Formation of hydrol yzed product of oxymetazoline 
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Target 
Concentration 
Level 
Concentration 
(mglmL) 
Response 
(peak Area) 
50% 0.0501 138465.97 
80% 0.08016 221667.44 
100% 0.1002 276757.8 
120% 0.12024 333323.64 
150% 0.1503 414777.48 
Slope 2761494.17 
Y Intercept (%) 296.75 
Correlation 0.99997 
Table 19: Linearity parameters for Oxymetazoline assay (1.=280 nm) 
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Figure 32: Linearity graph of oxymetazoline assay 
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Table 20 and Figure 33 show the linearity parameters and the linearity graph for 
oxymetazoline degradation method at wavelength 225 nm respectively. No carryover was 
observed into blank injections immediately after the highest level linearity standard of 
oxymetazoline, ensuring independence of the samples. In addition,' oxymetazoline HC] 
was found to be Hnear with 100 ilL injection volume at the same five concentration levels 
as the 10 ilL injection volume. A linearity graph was prepared by plotting the 
concentration versus the response of oxymetazoline. Table 21 and Figure 34 show the 
linearity parameters and the linearity graph for oxymetazoline assay method with 
injection volume 100 ilL and wavelength 280 nm. 
This wide linearity calibration range allows the analysis of a variety of possible 
formulations containing oxymetazoline HC] and is not limited only to ophthalmic 
solutions. It should be noted that method applicability should be explored for each 
formulation for possible interferences from the different formulation components that 
were used. 
System precision was established by six replicate measurements of a hypothetical 
formulation containing oxymetazoline HCl. The %RSD for OXY were found to be 0.8 
and 0.1 for the assay and degradation methods respectively. Furthermore, to make the 
method a QC friendly OXY and OXY-DEG were measured in a single injection. The 
system precision was evaluated at 100 III injection volume. Six replicate measurements 
of a 100% theoretical standard solution containing oxymetazoline hydrochloride were 
injected. The error contributed by the system, independent of the sample preparation, was 
less than the acceptance criteria of 2.0 %. 
125 

arget 
Concentration 
Level 
Concentration 
(mglmL) 
Response 
(Peak Area) 
70% 0.000708 111788.48 
80% 0.00081 127613.78 
90% 0.000911 143316.57 
100% 0.001012 160537.21 
130% 0.001316 206790.74 
Slope 156710120.41 
Y Intercept (%) 915.35 
Correlation 0.9997 
Table 20: Linearity parameters for oxymetazoline degradation method (A=225 nm) 
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Linearity'of Oxymetazoline 
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Figure 33: Linearity graph of oxymetazoline degradation method 
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Target 
Concentration 
Level 
Concentration 
(mg/mL) 
Response 
(peak Area) 
50% 0.05127 1436090.49 
70% 0.07169 2011388.93 
100% 0.10242 2871951.50 
120% 0.12290 3437903.64 
150% 0.15362 4281918.60 
Slope 27799761.12 
Y Intercept (%) 18880.01 
Correlation 0.99996 
Table 21: Linearity parameters for oxymetazoline degradation method (A=225 nm) with 100 J.l.L injection 
volume 
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linearity of Oxymetazoline lOOul injection 
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Figure 34: Linearity graph of oxymetazoline assay method at 280 nm and 100 /-tL injection volume 
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The %RSD for assay oxymetazoline was found to be 0.8 and 0.1 for 10 ilL and 100 ilL 
injection volumes respectively and the %RSD for oxymetazoline in degradation method 
was found to be 0.1 %. In both methods (assay & degradation) including the two different 
injection volumes for the assay method the %RSD was well below the 2.0% acceptance 
criteria. Comparison tables of the system precision results between the two methods and 
the two injections volumes are shown on Table 22a. 
The repeatability of the method was evaluated by six identical sample 
preparations of a homogeneous batch of an ophthalmic formulation and the results were 
found to be within specification. The percent relative standard deviation of the six 
preparations for both OXY injections of 10 III and 100 Jll were found to 0.2%. 
Comparison table of the results between the two injections volumes are shown on Table 
22b. The repeatability of the method was also evaluated for the OXY-DEG by six 
identical sample preparations of a homogeneous batch of a real formulation and the 
results were found to be within acceptance criteria. The percent relative standard 
deviation of the six preparations ofOXY-DEG was found to be 0.5%. In order to further 
validate the results, the experiment was conducted again on a different day, using a 
different mobile phase, instrument and column. The experimental mean agreements 
between the two tests were found to be 0.2 and 2.6 for OXY and OXY -DEG respectively, 
both of which are within the acceptance criteria. Further all individual and combined 
assay results for both experiments were acceptable. Detailed results ofOXY and OXY­
DEG are displayed in Table 22c. All the repeatability results were within acceptance 
criteria of 3.0%. 
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Oxymetazoline Assay standard Oxymetazoline Degradation 
0.10mglmL standard 
0.10 mg/mL 
Replicate # Area (10uL) Area (lOOuL) Area (100pL) I 
1 279044.40 2877393.58 152361.39 

2 
 278249.36 2877490.53 152834.99 

3' 
 274391.35 2878025.81 152749.44 

4 
 274136.23 2877960.56 152629.47 

5 
 273974.85 2879907.73 152350.66 

6 
 276623.72 2880944.21 152564.84 

Mean 
 276069.98 2878620.40 152581.80 

%RSD 
 0.8 0.1 0.1 
I 
I 
I 
I 
I 
(a) 
Oxymetazoline Theoretical Assay Value: 100% LC 
Replicate # %LC (10 ilL) %LC (100 ilL) r 
1 100.6 100.9 
2 100.6 100.6 I I 
I 3 100.8 100.8 I 
4 100.9 100.5 I 
5 101.2 100.6 
6 100.5 100.6 
Mean 100.8 100.7 i 
%RSD 0.2 0.2 
(b) 
% Label Claim (% LC) 
Replicate Oxymetazoline hydrochloride OXY·Degradant 
Experiment 1 Experiment 2 Experiment 1 Experiment 2 i 
1 100.6 100.6 109.2 108.6 I 
2 100.6 100.8 110.0 105.5 i 
3 100.S 100.2 lOS.6 105.S i 
4 100.9 100.5 lOS.5 107.6 I 
5 101.2 100.6 lOS.9 105.1 i 
6 100.5 100.6 108.7 106.4 
Mean 100.8 100.6 109.0 106.4 
%RSD 0.2 0.2 0.5 1.3 
Mean Agreement 0.2% 2.6% 
Table 22: Experimental results for (a) Comparison of oxymetazoline hydrochloride system precision data 
between 10 ilL and 100 ilL injection volumes (b) Comparison of oxymetazoline HCl method precision data 
between 10 ilL and 100 ilL injection volume (c) Comparison of oxymetazoline HC] and OXY-DEG for 
method precision by two different experiments 
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Accuracy was established by assaying three different concentration levels 70%, 
100%, and 130% of the hypothetical fonnulation concentration of OXY. Six preparations 
of ophthalmic solutions without oxymetazoline were spiked at each level, with standard 
of oxymetazoline and then solutions were injected into HPLC system for the assay 
method. For the degradation method accuracy was established by assaying four different 
degradant concentration levels 0.1 %, 1.0%, 1.5% and 3.0% of the hypothetical 
fonnulation concentration of oxymetazoline hydrochloride. Six preparations of 
ophthalmic solutions without oxymetazoline, at each level, were spiked with standard of 
OXY -DEG and then solutions were injected into HPLC system. Results are reported in 
Table 23. OXY mean recovery values varied from 100.0 to 100.4 % LC and OXY-DEG 
mean recovery values varied from 103.6 to 109.0. No bias was observed for the OXY 
since the results for the mean recovery from all three accuracy levels were not 
significantly lower or higher (±1.5%) than the theoretical value. The accuracy of the 
oxymetazoline HCI analytical assay method at 100 III injection volume was detennined at 
three working levels 60%, 100% and 140% of the theoretical concentration. Six 
preparations of OXY placebo were spiked with a standard at the three working levels of 
the theoretical concentration. The results for all three average values met acceptance 
criteria and were comparative to the results of the 10 ilL injection volume. OXY mean 
recovery values were varied from 99.5 to 100.5 and no bias was observed from all three 
levels. Comparison of the results between the two injection volumes at each accuracy 
level are shown on Table 24. 
The RRF was detennined by spiking OXY-DEG linearity solutions at three levels 
(0.1,1.0 and 3.0%) with OXY at the standard concentration. Injections were made in 
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Prep # OxymetazoJine HCI OXY.D~radant 
Mean Recovery Value %LC Mean Recoverv Value %LC , 
70% Level 100% Level 130% Level 0.1% Level 1.0% Level 1.5% Level 3.0% Level I 
1 99.S 99.7 99.7 109.2 109.S 103.5 102.7 
2 99.9 100.5 100.2 110.0 104.2 104.0 104.0 
3 100.2 101.1 99.S 10S.6 104.0 104.0 104.2 
4 100.2 100.7 100.1 lOS.5 104.1 103.S 103.1 
5 100.2 100.4 101.2 lOS.9 104.9 105.3 103.9 
6 100.0 100.0 101.0 lOS.7 104.6 104.9 104.0 
Mean 100.0 100.4 100.3 109.0 105.3 104.3 103.6 
%RSD 0.2 0.5 0.6 0.5 2.2 0.7 0.6 
i 
i 
! 
Table 23: Accuracy results (ophthalmic solution without oxymetazoline was spiked at three different levels 
for assay of OXY and four levels for the OXY-DEG) 
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OXYmetazoline HCI 
Replicate # 70% Recovery (10111) 60% Recovery (100,",,) 
1 99.8 100.2 
2 99.9 99.9 I 
3 100.2 100.1 
4 100.2 100.2 I 
5 100.2 99.2 I 
6 100.0 100.5 
Mean 100.0 100.0 
%RSD 0.2 O.S I 
(a) 
Oxymetazoline H CI 
Replicate # 100% Recovery (10ul) 100% Recovery (100ul) i 
1 99.7 99.9 i 
2 100.5 100.2 
3 lOLl 99.7 
4 100.7 100.1 I 
5 100.4 100.0 
6 100.0 100.3 
Mean 100.4 100.0 
%RSD O.S 0.2 
(b) 
Oxymetazoline HCI 
Replicate # 130% Recovery (10111) 140% Recovery (100 '"") 
I 99.7 99.4 
2 100.2 100.0 
3 99.8 99.6 
4 100.1 99.6 
5 101.2 99.5 
6 101.0 99.6 
Mean 100.3 99.6 
%RSD 0.6 0.2 
(c) 
Table 24: Comparison table of oxymetazoline HCI accuracy data between 10 ftL and 100 ",L injection 
volume: a) Level 60%, b) Level 100%, c) Level 140% 
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triplicate and the average response was used for the determination of the RRF. That 
value was corrected for the free base since the salt form of the degradant was used during 
the validation. The RRF value was determined to be 0.6993. 
The LOD and LOQ were determined by analyzing low concentration linearity 
standard solutions of OXY -DEG in triplicate to confirm acceptable results. The LOD was 
found to be 0.0001 mglmL for signal to noise ratio more than three and the LOQ was 
found to be 0.000025 mg/mL for signal to noise ratio more than twelve. 
The methods were unaffected by small, deliberate variations in chromatographic 
parameters and mobile phase preparation. The parameters under testing were wavelength, 
flow, column temperature, mobile phase ratio and pH of the buffer. The robustness 
results have shown that the retention time and the peak shape were not affected by the 
parameters under testing. The variation that was observed between the normal method 
conditions and the changed parameters were from 0 to ].3% for OXY assay. The 
stabilities of the standard and sample solutions for both OXY and OXY -DEG were 
evaluated. The standard of OXY is stable over a period of 168 hours and 240 hours in the 
assay method and shows no significant decrease in response over a period of 168 hours 
for OXY assay method in both sample and standard. The results are displayed in Table 25. 
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I 
Solution stability for Assay method 
OxymetazoIine Hel Standard 
Time Point Response % Difference 
from Initial 
Initial 100.7 
-
24 Hours 101.3 0.6 
72 Hours 102.2 1.5 
168 Hours lOlA 0.7 
Oxymetazoline Hel Sample 
Time Point Response % Difference 
from Initial 
Initial 99.9 -
24 Hours 100.6 0.7 
72 Hours 101.7 1.8 
168 Hours 99.8 0.1 
Solution stability for degradation method 
Oxymetazoline Hel Standard 
Time Point Response % Difference 
from Initial 
Initial 100.0 . 
96 Hours 98.2 1.8 
240 Hours 99.7 0.3 
OXY -Degradant 
Time Point Response % Difference 
from Initial 
Initial 106.8 . 
96 Hours 104.8 2.0 
240 Hours 105.1 1.7 
I 
I 
I 
Table 25: Solution stability results for Oxymetazoline standard for both assay and degradation methods. 
Solution stability of Oxymetazoline and Oxy-DEG in the sample. 
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5.4 Conclusion 
In this work, new methods for the determination of oxymetazoline hydrochloride 
and its degradation product in ophthalmic solutions are described. Simple dilution 
followed by isocratic HPLC with UV -detection is employed, generating a very 
straightforward method that might be applicable in a variety of applications. The method 
fully separates the oxymetazoline HC} from its degradant and other excipients. Testing 
parameters for these methods was performed according to ICH guidelines and met all 
acceptance criteria. The methods are precise, accurate, and linear at concentration ranges 
encompassing our hypothetical formulations and the known concentrations of many 
products containing these substances. 
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Overall Conclusions 
Over the counter ophthalmic solutions enable people to effectively treat 
symptoms of redness, dry eye, tear generation and other irritations of the eye. They are 
used worldwide and they are more affordable than their counterpart prescription 
ophthalmic solutions. As formulations get more complex with mUltiple components, 
targeting multiple symptoms, there is an increasing need for new analytical methods that 
are low cost, simple to operate, use straightforward instrumentation, while maintaining 
similar requirements to techniques employing more sophisticated instrumentation. 
The importance of preservatives in over the counter ophthalmic solutions is well 
known given the environment in which these solutions are kept. Often, users they stored 
the multidose bottles in medicine cabinets, purses, and pockets, exposed to extreme 
>conditions of heat and humidity provide a good environment for microbial growth. 
Benzalkonium chloride, one of the most commonly preservative systems in ophthalmic 
solutions was studied in this work. Separation of the benzalkonium chloride homologues 
from other formulation components was done with a simple, fast isocratic reversed phase 
chromatography method using UV detection. The separation of the homologues is 
dependent on mobile phase ratio, pH and buffer strength. The method was applicable to 
several different over the counter formulations that were use benzalkonium chloride as a 
preservative system. 
Lubricants are important substances to ophthalmic formulations because they are 
used to control solution viscosity and they are offer medicinal benefits by relieving pain 
in inflamed or irritated mucous membranes. Due to their importance in ophthalmic 
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solutions several lubricants (polyvinylpyrrolidone, PEG400 and glycerin) were studied in 
this work. 
The polyvinylpyrrolidone peak was eluted and separated before the void volume 
disturbance from other formulation components. Several unusual chromatographic 
situations were used together successfully in this work: Size exclusion chromatography 
with UV detection and quantitation of a chromatographic peak eluting before the void 
volume. This method provides a model for the analysis of a polymeric component in the 
presence of monomeric components in a number of different types of formulations. 
A simple size exclusion chromatography method using refractive index detection 
was presented. PEG400 and glycerin were separated simultaneously from other 
formulation components. In addition, the method appears to be capable of separating 
another demulcent, hydroxylpropyl methylcellulose (HPMC) from formulation 
components. The method provides a model for the simultaneous analysis of polymeric 
components in the presence of other formulation components in a number of different 
types of formulations. 
There are different active components in ophthalmic solutions for the treatment of 
variety of symptoms. A major category of active components in ophthalmic solutions is 
vasoconstrictors and they are used for the treatment of redness in the eye. A well known 
vasoconstrictor that used in the ophthalmic solutions is oxymetazoline. A new simple, 
fast, isocratic HPLC with UV -detection method for the determination of oxymetazoline 
hydrochloride and its degradation product in ophthalmic solutions was described. The 
method fully separates the oxymetazoline HCI from its degradant and other ophthalmic 
components and it might be applicable in a variety of other formulations. Stress studies of 
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other vasoconstrictors (naphazoline, tetrahydrozoline) with similar chemical structure 
indicate that they exhibit the same degradation pathway. 
In this work, several straight forward techniques for the analysis of components in 
ophthalmic solutions, each of which represents an improvement over previous literature 
techniques, are demonstrated. 
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